var title_f38_19_39216="Dexamethasone: Patient drug information";
var content_f38_19_39216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dexamethasone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/49/17172?source=see_link\">",
"       Dexamethasone (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/45/41686?source=see_link\">",
"       Dexamethasone (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11621 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39216=[""].join("\n");
var outline_f38_19_39216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/49/17172?source=related_link\">",
"      Dexamethasone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/45/41686?source=related_link\">",
"      Dexamethasone (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_19_39217="Patient information: Vancomycin-resistant enterococci (The Basics)";
var content_f38_19_39217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/33/35345\">",
"         Patient information: Central line infections (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/48/26370\">",
"         Patient information: Endocarditis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/34/2594\">",
"         Patient information: Primary biliary cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/47/20210\">",
"         Patient information: Urinary tract infections in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/18/32036\">",
"         Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vancomycin-resistant enterococci (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vancomycin-resistant-enterococci-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10195180\">",
"      <span class=\"h1\">",
"       What are vancomycin-resistant enterococci (VRE)?",
"      </span>",
"      &nbsp;&mdash;&nbsp;",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/34/17957?source=see_link\">",
"       Vancomycin",
"      </a>",
"      -resistant enterococci",
"      <strong>",
"      </strong>",
"      (also called &ldquo;VRE&rdquo;) are bacteria that cause an infection that is hard to cure. Enterococci are a kind of bacteria. Vancomycin is an antibiotic used to treat infections caused by enterococci. But some enterococci have learned to outsmart the medicines that doctors normally use to kill them. Doctors call this &ldquo;resistance.&rdquo;",
"     </p>",
"     <p>",
"      People carry all sorts of germs inside their body and on their skin. The body usually controls these germs, so they do no harm. Enterrococci are normally found in the intestines and the female sex organs. They are also found on surfaces in living spaces, especially bathrooms.",
"     </p>",
"     <p>",
"      Some people have VRE inside their bodies but do not get an infection. Doctors describe these people as having &ldquo;VRE colonization.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195195\">",
"      <span class=\"h1\">",
"       How do you catch VRE?",
"      </span>",
"      &nbsp;&mdash;&nbsp;VRE are common in hospitals and nursing homes. In these places, VRE have been found on bedrails, telephones, and medical equipment.",
"     </p>",
"     <p>",
"      VRE is spread through touch. Often, it is spread by the hands of a person (usually a doctor, nurse, or caregiver) who has touched someone or something with VRE. People can also catch VRE by touching a surface with VRE on it. VRE is not spread by coughing or sneezing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195210\">",
"      <span class=\"h1\">",
"       How do I know if I have a VRE infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;VRE can cause infections of the urinary tract (the organs that process urine), in the belly, or in the bloodstream. If your doctor suspects you have a VRE infection, he or she will do tests to check for VRE in your urine or blood. You might also need an imaging test, such a CT scan, that takes pictures of the inside of your body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195225\">",
"      <span class=\"h1\">",
"       Can VRE infections be treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor can give you special antibiotics to treat your infection. The antibiotics can be given as pills or through a tube in one of your veins. This tube is called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p>",
"      If you get medicines to take at home, it is very important that you follow the directions exactly. Take",
"      <strong>",
"       ALL",
"      </strong>",
"      &nbsp;the pills you are given, even if you feel better before you finish them. If you do not take them all, the bacteria could get resistance to the medicine you are taking.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195240\">",
"      <span class=\"h1\">",
"       Is there any way to prevent VRE colonization and infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People everywhere should wash their hands often with soap and water. This is especially important for people who are in the hospital or a nursing home. Washing your hands is the best way to prevent most infections.",
"     </p>",
"     <p>",
"      If you are a patient in a hospital, you should also make sure your doctors and nurses wash their&nbsp;hands before they touch you. If there is no sink, they can use an alcohol-based hand gel instead.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195255\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/47/20210?source=see_link\">",
"       Patient information: Urinary tract infections in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/48/26370?source=see_link\">",
"       Patient information: Endocarditis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/33/35345?source=see_link\">",
"       Patient information: Central line infections (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/34/2594?source=see_link\">",
"       Patient information: Primary biliary cirrhosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/18/32036?source=see_link\">",
"       Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/19/39217?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83755 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39217=[""].join("\n");
var outline_f38_19_39217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195180\">",
"      What are vancomycin-resistant enterococci (VRE)?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195195\">",
"      How do you catch VRE?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195210\">",
"      How do I know if I have a VRE infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195225\">",
"      Can VRE infections be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195240\">",
"      Is there any way to prevent VRE colonization and infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195255\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/33/35345?source=related_link\">",
"      Patient information: Central line infections (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/48/26370?source=related_link\">",
"      Patient information: Endocarditis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/34/2594?source=related_link\">",
"      Patient information: Primary biliary cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/18/32036?source=related_link\">",
"      Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/47/20210?source=related_link\">",
"      Patient information: Urinary tract infections in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_19_39218="Posterior vaginal prolapse";
var content_f38_19_39218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Evaluation of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: RG Rogers, MD, Division of Female Pelvic Medicine and Reconstructive Surgery, University of New Mexico Health Sciences Center, Albuquerque, NM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39218=[""].join("\n");
var outline_f38_19_39218=null;
var title_f38_19_39219="Scissor technique";
var content_f38_19_39219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scissor technique for opening the mouth during endotracheal intubation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thumb of the operator's right hand pushes the lower incisors (or mandibular gum) caudad while the index finger (placed posterior to the thumb) pushes the upper incisors (or maxillary gum) cephalad.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joshua Nagler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39219=[""].join("\n");
var outline_f38_19_39219=null;
var title_f38_19_39220="Radical stepwise ER Endosc";
var content_f38_19_39220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Radical stepwise mucosal resection in a patient with esophageal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 2 cm long segment of Barrett's esophagus is visible with a raised area subsequently found to correspond to a mucosal cancer (panels A to C). Electrocoagulation markers were placed to delineate the lesion (panel D) after which it was resected with the cap technique (panel E). A bleeding site was treated by placement of a hemoclip (panel F). Histologic evaluation of the resection specimen showed a mucosal cancer. The patient subsequently underwent stepwise complete resection of the residual Barrett's epithelium (panel G) resulting in complete neosquamous reepithelialization (panel H).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.Barrett.nl. Copyright &copy; Amsterdam Esophageal Research Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39220=[""].join("\n");
var outline_f38_19_39220=null;
var title_f38_19_39221="Unproven therapies for chronic systolic heart failure";
var content_f38_19_39221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unproven therapies for chronic systolic heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39221/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39221/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39221/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39221/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39221/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39221/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/19/39221/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic heart failure (HF), generally defined as New York Heart Association (NYHA) functional class II to IV (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ), is a common clinical syndrome associated with increased mortality primarily due to progressive pump dysfunction and sudden death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link\">",
"     \"Prognosis of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of HF is aimed at three goals: improvement in symptoms, slowing of disease progression, and prolongation of survival (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"mobipreview.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement in symptoms can be achieved by a variety of drugs, including digitalis, diuretics, ACE Inhibitors, angiotensin receptor blockers, and beta blockers.",
"     </li>",
"     <li>",
"      Possible reversible causes of heart failure such as coronary artery disease or valve disease should be investigated and treated. &nbsp;",
"     </li>",
"     <li>",
"      ACE inhibitors, beta blockers, and aldosterone antagonists improve survival in appropriately selected patients with systolic heart failure.",
"     </li>",
"     <li>",
"      Device therapy with an implantable cardioverter-defibrillator",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiac resynchronization therapy also confers survival benefit in selected patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unproven therapies for the treatment of chronic heart failure due to systolic dysfunction will be reviewed here. Standard therapy for systolic dysfunction, the management of diastolic dysfunction, and possibly effective emerging therapies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18809?source=see_link\">",
"     \"Possibly effective emerging therapies for heart failure\"",
"    </a>",
"    .) Included here are therapies that a) have been tested in clinical trials and found not to be useful, or b) have not yet undergone sufficient clinical testing to determine their utility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UNPROVEN THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endothelin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma levels of endothelin, a more potent vasoconstrictor than angiotensin II or norepinephrine, are frequently elevated in patients with severe HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/2\">",
"     2",
"    </a>",
"    ]. Experimental studies demonstrated that endothelin is released in part from cardiac myocytes and coronary vascular endothelium and suggested that acute intravenous and chronic oral therapy with an endothelin receptor antagonist might lead to improved left ventricular function and clinical benefits. However, three randomized trials have shown",
"    <strong>",
"     no benefit",
"    </strong>",
"    of chronic endothelin receptor blockade in patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/20/11592?source=see_link\">",
"     \"Role of endothelin in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vasopeptidase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopeptidase inhibitors simultaneously inhibit both neutral endopeptidase, which slows the metabolism of endogenous atrial natriuretic peptide, and angiotensin converting enzyme; these drugs reduce systolic and mean blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/6\">",
"     6",
"    </a>",
"    ] and renal vascular resistance and increase renal blood flow and sodium excretion in mild heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/7\">",
"     7",
"    </a>",
"    ]. They also improve hemodynamics, increase left ventricular ejection fraction (LVEF), and reduce left ventricular wall stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of vasopeptidase inhibitor omapatrilat in patients with heart failure was compared to an angiotensin converting enzyme (ACE) inhibitor in two randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The IMPRESS trial of 573 patients found that, compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    , omapatrilat improved the primary end point of exercise tolerance and reduced the combined end point of hospitalization or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The much larger OVERTURE trial compared omapatrilat (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    (10 mg twice daily) in 5770 patients with class II to IV heart failure who were receiving optimal medical therapy; all patients had heart failure for at least two months, an LVEF &le;30 percent, and had been hospitalized for heart failure in the preceding year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/11\">",
"     11",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the primary end point of death or heart failure hospitalization with omapatrilat (31.7 versus 33.7 percent for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      , hazard ratio 0.94, 95% CI 0.86-1.03) or in major secondary end points of cardiovascular death, myocardial infarction, stroke, or revascularization.",
"     </li>",
"     <li>",
"      There was a significant reduction in cardiovascular death or hospitalization (hazard ratio 0.91).",
"     </li>",
"     <li>",
"      The incidence of side effects was the same with the two drugs (including angioedema), except for hypotension, which was more common with omapatrilat (19.5 versus 11.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although further analysis may show that some subsets of patients would achieve greater benefit from vasopeptidase inhibitors, the fact that their effects are largely equivalent to ACE inhibitors casts uncertainty on their role as a primary therapy for heart failure, particularly due to concerns about the higher incidence of angioedema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/52/14149?source=see_link\">",
"     \"Vasopeptidase inhibition in the management of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Growth hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental studies suggest that growth hormone may be beneficial in heart failure. Initial clinical trials demonstrated an increase in left ventricular mass but hemodynamic improvement was inconsistent.",
"   </p>",
"   <p>",
"    There must be caution before the general application of GH administration in dilated cardiomyopathy is considered. The exact mechanism of benefit is uncertain, as are the long-term effects of this therapy on myocardial function. Prospective validation of the initial anecdotal observations is required. In 2005, an",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force did",
"    <strong>",
"     not",
"    </strong>",
"    recommend the use of growth hormone as a treatment for heart failure (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"mobipreview.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Flosequinan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flosequinan is a novel vasodilator that acts in part by phosphodiesterase inhibition. Controlled trials have demonstrated symptomatic improvement in patients already being treated with diuretics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and vasodilators. However, standard doses of flosequinan (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    are associated with",
"    <strong>",
"     increased mortality",
"    </strong>",
"    and this drug is not currently available for clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Epoprostenol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     Epoprostenol",
"    </a>",
"    (prostacyclin) is an effective therapy for patients with idiopathic pulmonary arterial hypertension and has been evaluated for the treatment of HF due to left ventricular dysfunction (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    ). However, the FIRST trial, which randomly assigned 471 patients with HF to a chronic infusion of epoprostenol or placebo, was prematurely terminated because the drug was associated with a strong trend toward decreased survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/13\">",
"     13",
"    </a>",
"    ]. Epoprostenol did not improve exercise capacity, quality of life, or reduce morbid events, despite an increase in cardiac index and reductions in pulmonary capillary wedge pressure and vascular resistance. The reason for this adverse outcome is not clear; a possible explanation is the significant positive inotropic effect of epoprostenol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Moxonidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moxonidine is a selective imidazoline agonist that acts specifically on central nervous system receptors to decrease sympathetic outflow. Since beta adrenoceptor antagonism has a beneficial effect on morbidity and mortality in HF, it was considered possible that central sympathetic blockade with this drug would also be effective.",
"   </p>",
"   <p>",
"    However, clinical trials with moxonidine failed to demonstrate a benefit of this agent in patients with HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The MOXCON trial was planned to evaluate the efficacy of moxonidine versus placebo in 4540 patients with class II to IV HF; this trial was terminated early (at one year from the beginning of enrollment) because of a higher mortality rate in the moxonidine group (5.0 versus 2.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The MOXSE trial, a study intended to establish optimal dosing for moxonidine in 268 patients, found a significant dose-related reduction in plasma norepinephrine concentrations with moxonidine but also a dose-related increase in serious adverse events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Coenzyme Q10",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coenzyme Q10 is a vitamin-like, fat soluble quinone found in high concentrations in the mitochondria of the heart, liver, and kidney, where it is involved in electron and proton transfer during oxidative phosphorylation. It is also an antioxidant and free radical scavenger with membrane stabilizing properties.",
"   </p>",
"   <p>",
"    Myocardial biopsies from patients with heart failure have demonstrated depletion of coenzyme Q10, an observation that provided the rationale for randomized controlled trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A double-blind randomized crossover trial included 30 patients with cardiomyopathy (mean left ventricular ejection fraction 26 percent) who were treated with coenzyme Q10 or placebo, each for three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/17\">",
"       17",
"      </a>",
"      ]. Coenzyme Q10 had no effect on left ventricular ejection fraction, cardiac volumes, hemodynamics, or quality of life indices.",
"     </li>",
"     <li>",
"      A second trial randomly assigned 55 patients with NYHA class III or IV heart failure who were receiving standard medical therapy to coenzyme Q10 or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/18\">",
"       18",
"      </a>",
"      ]. At six months, there was no change in either group in left ventricular ejection fraction, peak oxygen consumption, or exercise duration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based in part on these observations, coenzyme Q10 was",
"    <strong>",
"     not",
"    </strong>",
"    recommended as a therapy for heart failure by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anti-TNF alpha therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental and human studies suggest that tumor necrosis factor alpha (TNFa) contributes to the progression of HF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12872?source=see_link\">",
"     \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, drugs that inhibit TNFa might be beneficial in patients with HF. Two strategies have been employed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      is a soluble receptor fusion protein that binds to TNFa and functionally inactivates it",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      is an antibody that is directed against the TNFa receptor, thereby interfering with the binding of TNFa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, two large trials with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (RECOVER and RENAISSANCE), the long term follow-up of the RECOVER and RENAISSANCE patients (RENEWAL), and a pilot trial with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (ATTACH) failed to show an improvement in clinical HF or morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In addition, there is evidence that anti-TNFa therapy may be associated with an increased risk of new-onset HF in the absence of other risk factors for the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39221/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link&amp;anchor=H18#H18\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H570358\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of HF is aimed at three goals: improvement in symptoms, slowing of disease progression, and prolongation of survival. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommended therapy for systolic heart failure and diastolic heart failure is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"       \"Treatment and prognosis of diastolic heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heart failure is associated with numerous biochemical derangements which have suggested potential targets for therapy. However, many proposed therapies lack proven benefit and some may cause harm. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Unproven therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/1\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/2\">",
"      Kiowski W, S&uuml;tsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/3\">",
"      Williams ES, Miller JM. Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session. J Am Coll Cardiol 2002; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     Data presented at ACC 50th Annual Session, Orlando, Florida, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/5\">",
"      Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/6\">",
"      McClean DR, Ikram H, Garlick AH, Crozier IG. Effects of omapatrilat on systemic arterial function in patients with chronic heart failure. Am J Cardiol 2001; 87:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/7\">",
"      Chen HH, Schirger JA, Chau WL, et al. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 1999; 100:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/8\">",
"      McClean DR, Ikram H, Garlick AH, et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000; 36:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/9\">",
"      Corti R, Burnett JC Jr, Rouleau JL, et al. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001; 104:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/10\">",
"      Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/11\">",
"      Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/12\">",
"      Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Circulation 1993; 88:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/13\">",
"      Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/14\">",
"      Montalescot G, Drobinski G, Meurin P, et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol 1998; 82:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/15\">",
"      Coats AJ. Heart Failure 99 -- the MOXCON story. Int J Cardiol 1999; 71:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/16\">",
"      Swedberg K, Bristow MR, Cohn JN, et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 2002; 105:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/17\">",
"      Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999; 33:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/18\">",
"      Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000; 132:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/19\">",
"      Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/20\">",
"      Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/21\">",
"      Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39221/abstract/22\">",
"      Kwon HJ, Cot&eacute; TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138:807.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3513 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39221=[""].join("\n");
var outline_f38_19_39221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H570358\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UNPROVEN THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endothelin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vasopeptidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Growth hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Flosequinan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Epoprostenol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Moxonidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Coenzyme Q10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anti-TNF alpha therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H570358\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3513\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3513|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/1/40989\" title=\"table 2\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12872?source=related_link\">",
"      Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18809?source=related_link\">",
"      Possibly effective emerging therapies for heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/20/11592?source=related_link\">",
"      Role of endothelin in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/52/14149?source=related_link\">",
"      Vasopeptidase inhibition in the management of hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_19_39222="Layers of amnion chorion";
var content_f38_19_39222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Layers of amnion chorion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39222=[""].join("\n");
var outline_f38_19_39222=null;
var title_f38_19_39223="Growth failure after childhood cancer: Role of hypothyroidism";
var content_f38_19_39223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growth failure after childhood cancer: Role of hypothyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39223/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39223/contributors\">",
"     Susan R Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39223/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39223/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39223/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39223/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/19/39223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of poor growth in childhood cancer survivors cannot always be identified. It often is caused by the toxic effects of chemotherapy, radiation effects on bone growth centers, or growth hormone deficiency, but it also may be caused by undiagnosed mild primary or central hypothyroidism.",
"   </p>",
"   <p>",
"    In childhood cancer survivors, hypothyroidism is cause for poor growth and is a complication of therapy, most commonly due to radiation therapy to either the brain (central hypothyroidism) or neck (primary hypothyroidism) and less frequently due to chemotherapy. Early identification and treatment of hypothyroidism improves the quality of life and optimizes the final adult height of these patients.",
"   </p>",
"   <p>",
"    The normal regulation of thyroid hormones and the diagnosis and treatment of hypothyroidism in childhood cancer survivors are reviewed here. Growth hormone (GH) deficiency after childhood cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS FOR GROWTH FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The growth rate of children who are undergoing treatment for cancer typically is slow. The slow growth velocity may result from neuraxis, mantle, or total body irradiation, chemotherapy, decreased nutritional intake, increased metabolic needs, or intercurrent illness (",
"    <a class=\"graphic graphic_figure graphicRef66717 \" href=\"mobipreview.htm?39/2/39968\">",
"     figure 1",
"    </a>",
"    ). The growth rate usually improves or shows \"catch up\" after completion of therapy (",
"    <a class=\"graphic graphic_figure graphicRef66717 \" href=\"mobipreview.htm?39/2/39968\">",
"     figure 1",
"    </a>",
"    ). Children whose growth rate does not improve or whose growth rate is less than the mean for age and gender should be evaluated for growth failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Growth failure in childhood cancer survivors is caused by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cranial irradiation",
"     </li>",
"     <li>",
"      Radiation to growth centers (eg, in bone marrow transplant recipients)",
"     </li>",
"     <li>",
"      Radiation to the spine",
"     </li>",
"     <li>",
"      Inadequate weight gain",
"     </li>",
"     <li>",
"      Chronic unresolved illness",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Hormone deficiency",
"     </li>",
"     <li>",
"      Hypothalamic-pituitary disorders secondary to tumor, surgery, chemotherapy, or cranial irradiation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=see_link\">",
"       \"Causes of hypopituitarism\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Late growth failure is common in children who received cranial radiotherapy, total body irradiation, and chemotherapy. In particular, cranial radiotherapy causes growth hormone (GH), gonadotropin, and thyrotropin deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. Spinal irradiation may result in poor growth of the spine, with relative sparing of limb growth. Primary hypothyroidism can occur if the thyroid gland was in the radiation field. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GH deficiency commonly is thought to be the first hypothalamic-pituitary deficiency to emerge after radiation therapy, followed by gonadotropin, adrenocorticotropic hormone (ACTH), and thyroid stimulating hormone (TSH), but these deficiencies can occur in any order [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/11\">",
"     11",
"    </a>",
"    ]. Hypothyroidism is found to be at least as prevalent as GH deficiency in cancer survivors when sensitive testing methods are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/7/7286?source=see_link\">",
"     \"Endocrine surveillance in childhood cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THYROID AXIS REGULATION IN NORMAL INDIVIDUALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like growth hormone (GH), thyroid stimulating hormone (TSH) is synthesized in anterior pituitary cells in response to a releasing hormone. Thyrotropin (or TSH)-releasing hormone (TRH) is secreted from the hypothalamus and transported to the pituitary via the venous portal system. Dopamine and somatostatin (which inhibit TSH release) also are transported from the hypothalamus. In persons of all ages, TSH concentrations are low in the afternoon, rise dramatically (\"surge\") after 1900 h, and reach the highest concentration between 2200 h and 0400 h [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Thus, at least one-third of the trophic influence of TSH on the thyroid gland occurs at night. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TRH is necessary for TSH synthesis, post-translational glycosylation of the alpha and beta subunits of TSH, and secretion of a fully bioactive TSH molecule from the pituitary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Altered TSH glycosylation, resulting in altered bioactivity, is seen in mixed hypothyroidism (central hypothyroidism with elevated TSH) (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TSH stimulates the thyroid gland to produce thyroxine (T4) and triiodothyronine (T3). Plasma T4 and T3 circulate in the bloodstream bound to thyroxine-binding globulin and albumin; only small amounts are free or unbound. Free T4 undergoes intracellular deiodination to form free T3, which interacts with DNA in the cell nucleus to influence cellular mRNA and protein synthesis. Both T4 and T3 provide negative feedback at the hypothalamus and pituitary to modulate TRH and TSH secretion.",
"   </p>",
"   <p>",
"    The free T4 concentration in an individual remains fairly stable over time at an optimal \"set point\" for thyroid function. The intact pituitary increases TSH secretion if free T4 production declines (as in primary hypothyroidism). Conversely, in central hypothyroidism, hypothalamic-pituitary release of TSH is impaired and free T4 declines as a result of decreased stimulation; the patient is just as hypothyroid, but the TSH concentration usually is not elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103572081\">",
"    <span class=\"h1\">",
"     THYROID DISEASE IN CANCER SURVIVORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103571974\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid dysfunction is one of the most common hormone abnormalities in childhood cancer survivors. This was illustrated in a retrospective review of 360 Finnish childhood cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Of the 291 patients who were tested, 71 (24 percent) had impaired thyroid function defined as a free T4 level below or a thyroid stimulating hormone (TSH) level above the normal range on two consecutive measurements, or the initiation of thyroxine replacement therapy. This included 30 of 65 patients with brain tumors, 10 of 21 with Hodgkin lymphoma, 19 of 140 with leukemia or non-Hodgkin lymphoma, and 12 of 65 with other tumors. Radiation therapy alone or with chemotherapy compared to chemotherapy alone was associated with higher risk of thyroid dysfunction (HR 4.68, 95% CI 2.0 to 10.8, and HR 2.9 95% CI 1.7 to 5.0, respectively).",
"   </p>",
"   <p>",
"    In a follow-up of 17,981 British adult survivors of childhood cancer diagnosed between 1940 and 1991, 10,483 returned a questionnaire [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/24\">",
"     24",
"    </a>",
"    ]. Of survivors, 19.9 percent of those treated for Hodgkin lymphoma, 15.3 percent of CNS neoplasms, 6.2 percent of non-Hodgkin lymphoma, and 5.2 percent of leukemia survivors had primary hypothyroidism.",
"   </p>",
"   <p>",
"    Other studies have also demonstrated the risk of thyroid disease in childhood survivors with specific malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/25-32\">",
"     25-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hodgkin lymphoma &ndash; In a review of the literature, the most common thyroid disorder in 4012 Hodgkin lymphoma survivors was primary hypothyroidism caused by radiotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/25\">",
"       25",
"      </a>",
"      ]. Thyroid carcinoma was not observed after chemotherapy alone.",
"     </li>",
"     <li>",
"      Craniopharyngioma &ndash; Of 55 adult patients with craniopharyngioma, 96 percent had central hypothyroidism, along with 84 percent having adrenocorticotropic hormone (ACTH) deficiency, 53 percent having diabetes insipidus, 50 percent having hypogonadism, and 65 percent having obesity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leukemia &ndash; Of 3579 five-year leukemia survivors in a report from the Childhood Cancer Survivor Study, 1.6 percent had hypothyroidism, and 0.6 percent had hyperthyroidism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nasopharyngeal carcinoma &ndash; Among 59 survivors of childhood nasopharyngeal carcinoma, 43 percent developed primary hypothyroidism, and 14 percent developed growth hormone (GH) deficiency at 15 year follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/30\">",
"       30",
"      </a>",
"      ]. All patients received radiotherapy to the primary tumor, and most received cervical radiation therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, after total body irradiation for hematopoietic cell transplant, the reported risk of primary hypothyroidism from a single center was 34 percent, while only 6 percent of patients treated with chemotherapy alone developed primary hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Types of hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hypothyroidism and GH deficiency are the most common hormone deficiencies that contribute to poor growth in childhood cancer, the combined incidence of primary, central, and mixed hypothyroidism may exceed the incidence of GH deficiency in childhood cancer survivors. In addition to slow growth, mild hypothyroidism causes fatigue, dry skin, constipation, increased sleep requirement, and cold intolerance (",
"    <a class=\"graphic graphic_table graphicRef62676 \" href=\"mobipreview.htm?41/41/42651\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary hypothyroidism typically occurs after total body radiation or radiation to the nasopharynx, neck, or spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Central and mixed hypothyroidism occur after radiation to the head (eg, for brain or nasopharyngeal tumors) or total body radiation. Primary and central hypothyroidisms are caused less commonly by chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/26,33\">",
"     26,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Primary hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hypothyroidism (reduced function of the thyroid gland manifested by low free T4 and elevated TSH) is the most common form of hypothyroidism in the general population and in cancer survivors. TSH elevation was observed in 39 percent of patients after mantle irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]. Thyroid gland volume was decreased in hypothyroid irradiated patients compared to those patients with normal thyroid function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary hypothyroidism is most likely to occur in patients who have received mantle irradiation for Hodgkin disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/25,32,35\">",
"     25,32,35",
"    </a>",
"    ], craniospinal radiation for medulloblastoma, or total body irradiation before bone marrow transplantation (BMT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/9,27\">",
"     9,27",
"    </a>",
"    ]. Primary hypothyroidism is rarely an isolated endocrinopathy in cancer survivors; they may also have GH deficiency, ACTH deficiency, or pubertal disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies of thyroid function after treatment for brain tumors use TSH elevation to identify thyroid dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/36\">",
"     36",
"    </a>",
"    ]. Most patients with mildly elevated TSH concentrations and normal T4 or free T4 are considered to have mild or \"compensated hypothyroidism.\" However, mild primary hypothyroidism is clinically important in children: children with normal concentrations of T4 and mild elevation of TSH do not grow as well as do other children who have TSH of 1 or 2",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/20\">",
"     20",
"    </a>",
"    ]. Thyroid replacement therapy in these children improves growth velocity, lipid profile, and energy level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Central hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central hypothyroidism refers to thyroid hormone deficiency caused by a disorder of the pituitary, hypothalamus, or hypothalamic-pituitary portal circulation. Free T4 and T4 values are similar to those seen in mild primary hypothyroidism, but the \"red flag\" of an elevated TSH is absent because the ability to increase TSH secretion is impaired. The blunted or absent nocturnal TSH surge in central hypothyroidism suggests loss of the normal circadian variation in TRH release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/6/18536?source=see_link\">",
"     \"Central hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The measurement of nocturnal TSH surge increases the ability to detect central hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/12,14,37\">",
"     12,14,37",
"    </a>",
"    ]. Using this method, central hypothyroidism, defined by a blunted TSH surge, is more common than previously suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/12\">",
"     12",
"    </a>",
"    ]. Central hypothyroidism occurs in as many as 95 percent of craniopharyngioma survivors, 65 percent of the survivors of brain or nasopharyngeal tumors, 35 percent of bone marrow transplant recipients, and 10 to 15 percent of leukemia survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/12,28,37\">",
"     12,28,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mixed hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed hypothyroidism consists of central hypothyroidism with mild TSH elevation (5 to 15",
"    <span class=\"nowrap\">",
"     mU/L).",
"    </span>",
"    TSH secretory dynamics are abnormal. TSH concentrations are elevated with a blunted or absent TSH surge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In contrast, the TSH surge is normal in primary hypothyroidism.",
"   </p>",
"   <p>",
"    Mixed hypothyroidism may reflect either separate injuries to the thyroid gland and the hypothalamus (eg, radiation injury of both structures) or central hypothyroidism with reduced biologic activity of TSH caused by abnormal glycosylation or reduced TRH release from the hypothalamus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/16-19,36,38\">",
"     16-19,36,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 208 childhood cancer survivors who were referred for evaluation of possible hypothyroidism or hypopituitarism, mixed hypothyroidism was present in 15 (7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/12\">",
"     12",
"    </a>",
"    ]. It was most prevalent (86 percent) among patients who had received total body or craniospinal radiation doses &gt;30 GY or a bone marrow transplant preparatory regimen. All of the patients with mixed hypothyroidism had free T4 concentrations in the low part of the normal range; 11 had elevations of basal TSH, and eight had abnormal TRH tests. Thus, both the TRH test and the TSH surge test were required to make the diagnosis.",
"   </p>",
"   <p>",
"    TSH secretory dysregulation after irradiation may precede other endocrine disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One year after receiving cranial irradiation for nasopharyngeal carcinoma, 90 percent of 31 adult patients had a delayed peak TSH response to TRH (suggestive of central hypothyroidism). Five years after radiation therapy, 64 percent had GH deficiency, 31 percent had gonadotropin deficiency, and 27 percent had ACTH deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8250?source=see_link\">",
"       \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In seven children with brain tumors who were studied prospectively after &gt;30 GY cranial radiation, the TSH surge became blunted before the onset of reduced GH concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Of patients diagnosed with central hypothyroidism, 34 percent had dysregulation of TSH secretion before development of GH deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the diagnosis of hypothyroidism may be delayed in up to one-third of patients if TSH secretion is not tested until GH deficiency becomes apparent. Such a delay may be acceptable in a minimally symptomatic adult. However, the lost growth opportunities and potential functional implications of hypothyroidism in children require early intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Thyroid nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who receive neck irradiation are at an increased risk of developing thyroid nodules and cancer. In one study, 20 percent of patients who received neck irradiation developed thyroid nodules over a 20 year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/41\">",
"     41",
"    </a>",
"    ]. In these patients, there was an 18-fold increased risk of thyroid cancer compared to the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of a history of cranial or total body radiation, slow growth rate, delayed bone maturation, and declining free T4 or free T4 below the lower limits of normal, or TSH above the upper limits of normal are consistent with a diagnosis of hypothyroidism (",
"    <a class=\"graphic graphic_table graphicRef60453 \" href=\"mobipreview.htm?42/48/43787\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Central hypothyroidism is difficult to diagnose because of its subtle clinical and laboratory presentation. It is particularly difficult to recognize in patients whose growth is complete because slowed growth rate can no longer be used as a sign. Symptoms of central hypothyroidism (eg, asthenia, edema, drowsiness, adynamia, skin dryness) may be of gradual onset and go unrecognized until therapy is begun and the patient feels better [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/42\">",
"     42",
"    </a>",
"    ]. In these patients, free T4 and serum TSH are the best measures of thyroid status. Free T4 below the normal range without TSH elevation is strongly suggestive of central hypothyroidism. However, patients with central hypothyroidism may have free T4 concentrations in the lowest one-third of the normal range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/12,18,20\">",
"     12,18,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients in whom there is a clinical suspicion for central hypothyroidism, treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/47/31480?source=see_link\">",
"     levothyroxine",
"    </a>",
"    is initiated with a goal of keeping T4 levels in the mid-normal reference range. A ratio of 8 am to 4 pm TSH less than 1.3 can be used to confirm central or mixed hypothyroidism, if the free T4 is in the lowest one-third of the normal range and TSH is normal or only mildly elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Hormone replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103572430\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yearly measurement of TSH and free T4 and growth surveillance are recommended in childhood cancer survivors. Early diagnosis of mild hypothyroidism permits early intervention to improve growth velocity and quality of life. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/7/7286?source=see_link\">",
"     \"Endocrine surveillance in childhood cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a survivor of childhood cancer who has slow growth or other symptoms of hypothyroidism, the criteria for starting thyroid hormone therapy without further diagnostic testing (in a not ill patient) include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TSH above 4",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      at 0800 or 0900 h, or above 3 mU",
"      <span class=\"nowrap\">",
"       /L",
"      </span>",
"      between 1000 h and 2000 h (regardless of the free T4 value) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Free T4 at or below the lower limits of the normal range for the assay (regardless of the TSH value).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No thyroid replacement therapy is needed if free T4 is in the upper two-thirds of the normal range and TSH does not meet the above criteria. The thyroid status and growth velocity should be reassessed annually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hormone replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical thyroid replacement dose for healthy children and adolescents with TSH less than 30",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    is",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/47/31480?source=see_link\">",
"     levothyroxine",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    PO each morning). Children older than three years of age who have TSH greater than 30",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    or in whom there are concerns about medical stability can be started at levothyroxine (0.75",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    PO each morning) and increased by 0.75",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    each month to permit more gradual physiologic and psychological adjustment to the new metabolic state. Thyroid hormone concentrations should be measured after four weeks of therapy because levothyroxine has a long half-life (five to six days). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=see_link&amp;anchor=H21#H21\">",
"     \"Acquired hypothyroidism in childhood and adolescence\", section on 'Treatment and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/47/31480?source=see_link\">",
"     levothyroxine",
"    </a>",
"    dose is adjusted as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary hypothyroidism &mdash; TSH is the most useful test to monitor during therapy; the goal is a TSH between 0.5 and 2",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      and no symptoms of over-replacement (eg, new onset of difficulty falling asleep at night or elevated heart rate).",
"     </li>",
"     <li>",
"      Central or mixed hypothyroidism &mdash; Monitoring TSH in these patients is not useful unless the initial TSH was elevated. In addition, therapy with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/47/31480?source=see_link\">",
"       levothyroxine",
"      </a>",
"      rapidly suppresses TSH (before resolution of clinical symptoms). In one prospective study of 37 patients with central hypothyroidism, free T4 and free T3 were monitored during therapy and dose adjusted to achieve free T4 in the midnormal range without free T3 elevation and without symptoms of hypo- or hyperthyroidism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39223/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, thyroid hormone replacement therapy in patients with central hypothyroidism is adjusted to keep their free T4 just above the middle of the normal range. The range of targeted free T4 levels used depends upon normative values of the clinical laboratory used to perform the assay:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abbott IMX assay &ndash; free T4 target range is 1.4 to 1.6",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (normal range, 0.78 to 1.85",
"      <span class=\"nowrap\">",
"       ng/dL)",
"      </span>",
"     </li>",
"     <li>",
"      Quest free T4 by dialysis assay &ndash; free T4 target range is 2 to 2.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (normal range 1 to 2.84",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the effects on the thyroid gland, cancer therapy may affect adrenal function. Thyroid hormone replacement can precipitate clinical decompensation in patients with unrecognized adrenal insufficiency because increase in thyroid levels may improve metabolic clearance of cortisol. Thus, it is necessary to evaluate patients for primary adrenal insufficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypothalamic ACTH deficiency and, if present, to treat them with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    before initiating thyroid therapy. The author usually initiates cortisol replacement in patients who have coexistent ACTH deficiency three days before beginning thyroid hormone therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38151?source=see_link\">",
"     \"ACTH deficiency in survivors of childhood cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In childhood cancer survivors, growth failure is a common complication in childhood cancer survivors and can be caused by a variety of different causes (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Differential diagnosis for growth failure'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypothyroidism is a cause of poor growth and is a common complication of radiation therapy to either the brain (central hypothyroidism) or neck (primary hypothyroidism), and less frequently due to chemotherapy. (See",
"      <a class=\"local\" href=\"#H103572081\">",
"       'Thyroid disease in cancer survivors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of a history of cranial or total body radiation, slow growth rate, delayed bone maturation, and declining free T4 or free T4 below the lower limits of normal, or thyroid stimulating hormone (TSH) above the upper limits of normal are consistent with a diagnosis of hypothyroidism (",
"      <a class=\"graphic graphic_table graphicRef60453 \" href=\"mobipreview.htm?42/48/43787\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Yearly measurement of TSH and free T4 and growth surveillance are recommended in childhood cancer survivors. Early diagnosis of mild hypothyroidism permits early intervention to improve growth velocity and quality of life. (See",
"      <a class=\"local\" href=\"#H103572430\">",
"       'Screening'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/7/7286?source=see_link&amp;anchor=H5#H5\">",
"       \"Endocrine surveillance in childhood cancer survivors\", section on 'Monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In cancer survivors with hypothyroidism, we recommend thyroid replacement therapy. Therapy is started in patients with slow growth or other symptoms of hypothyroidism, and who have laboratory evidence of hypothyroidism. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/1\">",
"      Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 1998; 19:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/2\">",
"      Brennan BM, Rahim A, Mackie EM, et al. Growth hormone status in adults treated for acute lymphoblastic leukaemia in childhood. Clin Endocrinol (Oxf) 1998; 48:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/3\">",
"      Sklar CA. Growth and neuroendocrine dysfunction following therapy for childhood cancer. Pediatr Clin North Am 1997; 44:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/4\">",
"      Ogilvy-Stuart AL, Shalet SM. Growth and puberty after growth hormone treatment after irradiation for brain tumours. Arch Dis Child 1995; 73:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/5\">",
"      Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/6\">",
"      Clarson CL, Del Maestro RF. Growth failure after treatment of pediatric brain tumors. Pediatrics 1999; 103:E37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/7\">",
"      Collet-Solberg PF, Sernyak H, Satin-Smith M, et al. Endocrine outcome in long-term survivors of low-grade hypothalamic/chiasmatic glioma. Clin Endocrinol (Oxf) 1997; 47:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/8\">",
"      Perkins JL, Kunin-Batson AS, Youngren NM, et al. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer 2007; 49:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/9\">",
"      Shalitin S, Phillip M, Stein J, et al. Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant 2006; 37:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/10\">",
"      Rutter MM, Rose SR. Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr 2007; 19:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/11\">",
"      Lam KS, Tse VK, Wang C, et al. Effects of cranial irradiation on hypothalamic-pituitary function--a 5-year longitudinal study in patients with nasopharyngeal carcinoma. Q J Med 1991; 78:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/12\">",
"      Rose SR, Lustig RH, Pitukcheewanont P, et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab 1999; 84:4472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/13\">",
"      Rose SR, Nisula BC. Circadian variation of thyrotropin in childhood. J Clin Endocrinol Metab 1989; 68:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/14\">",
"      Rose SR. Improved diagnosis of mild hypothyroidism using time-of-day normal ranges for thyrotropin. J Pediatr 2010; 157:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/15\">",
"      Abel ED, Kaulbach HC, Campos-Barros A, et al. Novel insight from transgenic mice into thyroid hormone resistance and the regulation of thyrotropin. J Clin Invest 1999; 103:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/16\">",
"      Persani L. Hypothalamic thyrotropin-releasing hormone and thyrotropin biological activity. Thyroid 1998; 8:941.",
"     </a>",
"    </li>",
"    <li>",
"     Manasco PK, et al. Thyrotropin abnormalities in central hypothyroidism. In: Glycoprotein Hormones: Structure, Function and Clinical Implications, Serono Symposia, Lustbader JW, Puett D, Ruddon RW (Eds), Springer-Verlag, 1994. p.343.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/18\">",
"      Rose SR, Manasco PK, Pearce S, Nisula BC. Hypothyroidism and deficiency of the nocturnal thyrotropin surge in children with hypothalamic-pituitary disorders. J Clin Endocrinol Metab 1990; 70:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/19\">",
"      Lee KO, Persani L, Tan M, et al. Thyrotropin with decreased biological activity, a delayed consequence of cranial irradiation for nasopharyngeal carcinoma. J Endocrinol Invest 1995; 18:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/20\">",
"      Rose SR. Isolated central hypothyroidism in short stature. Pediatr Res 1995; 38:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/21\">",
"      Pitukcheewanont P, Rose SR. Nocturnal TSH surge: A sensitive diagnostic test for central hypothyroidism in children. Endocrinologist 1997; 7:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/22\">",
"      Madanat LM, L&auml;hteenm&auml;ki PM, Alin J, Salmi TT. The natural history of thyroid function abnormalities after treatment for childhood cancer. Eur J Cancer 2007; 43:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/23\">",
"      Madanat LM, L&auml;hteenm&auml;ki PM, Hurme S, et al. Hypothyroidism among pediatric cancer patients: a nationwide, registry-based study. Int J Cancer 2008; 122:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/24\">",
"      Brabant G, Toogood AA, Shalet SM, et al. Hypothyroidism following childhood cancer therapy-an under diagnosed complication. Int J Cancer 2012; 130:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/25\">",
"      van Dorp W, van Beek RD, Laven JS, et al. Long-term endocrine side effects of childhood Hodgkin's lymphoma treatment: a review. Hum Reprod Update 2012; 18:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/26\">",
"      Izaki S, Goto H, Okuda K, et al. Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. Int J Hematol 2007; 86:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/27\">",
"      Felicetti F, Manicone R, Corrias A, et al. Endocrine late effects after total body irradiation in patients who received hematopoietic cell transplantation during childhood: a retrospective study from a single institution. J Cancer Res Clin Oncol 2011; 137:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/28\">",
"      Crom DB, Smith D, Xiong Z, et al. Health status in long-term survivors of pediatric craniopharyngiomas. J Neurosci Nurs 2010; 42:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/29\">",
"      Chow EJ, Friedman DL, Stovall M, et al. Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2009; 53:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/30\">",
"      Cheuk DK, Billups CA, Martin MG, et al. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer 2011; 117:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/31\">",
"      Hancock SL, McDougall IR, Constine LS. Thyroid abnormalities after therapeutic external radiation. Int J Radiat Oncol Biol Phys 1995; 31:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/32\">",
"      Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000; 85:3227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/33\">",
"      Rose SR, Schreiber RE, Kearney NS, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 2004; 17:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/34\">",
"      Bonato C, Severino RF, Elnecave RH. Reduced thyroid volume and hypothyroidism in survivors of childhood cancer treated with radiotherapy. J Pediatr Endocrinol Metab 2008; 21:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/35\">",
"      Khoo VS, Liew KH, Crennan EC, et al. Thyroid dysfunction after mantle irradiation of Hodgkin's disease patients. Australas Radiol 1998; 42:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/36\">",
"      Ogilvy-Stuart AL, Shalet SM, Gattamaneni HR. Thyroid function after treatment of brain tumors in children. J Pediatr 1991; 119:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/37\">",
"      Pasqualini T, McCalla J, Berg S, et al. Subtle primary hypothyroidism in patients treated for acute lymphoblastic leukemia. Acta Endocrinol (Copenh) 1991; 124:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/38\">",
"      Rose SR. Disorders of thyrotropin synthesis, secretion, and function. Curr Opin Pediatr 2000; 12:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/39\">",
"      Spoudeas HA, Hindmarsh PC, Matthews DR, Brook CG. Evolution of growth hormone neurosecretory disturbance after cranial irradiation for childhood brain tumours: a prospective study. J Endocrinol 1996; 150:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/40\">",
"      Merchant TE, Williams T, Smith JM, et al. Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. Int J Radiat Oncol Biol Phys 2002; 54:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/41\">",
"      von der Weid NX. Adult life after surviving lymphoma in childhood. Support Care Cancer 2008; 16:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39223/abstract/42\">",
"      Ferretti E, Persani L, Jaffrain-Rea ML, et al. Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab 1999; 84:924.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6239 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39223=[""].join("\n");
var outline_f38_19_39223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS FOR GROWTH FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THYROID AXIS REGULATION IN NORMAL INDIVIDUALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103572081\">",
"      THYROID DISEASE IN CANCER SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103571974\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Types of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Primary hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mixed hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103572430\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hormone replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6239\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6239|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/2/39968\" title=\"figure 1\">",
"      Growth in childhood cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6239|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/41/42651\" title=\"table 1\">",
"      Symptoms and signs of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/48/43787\" title=\"table 2\">",
"      Thyroid evaluation CA survivors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38151?source=related_link\">",
"      ACTH deficiency in survivors of childhood cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/7/7286?source=related_link\">",
"      Endocrine surveillance in childhood cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31607?source=related_link\">",
"      Growth failure after childhood cancer: Role of growth hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8250?source=related_link\">",
"      Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_19_39224="Life cycle African trypanosomiasis";
var content_f38_19_39224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F85844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F85844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 631px\">",
"   <div class=\"ttl\">",
"    Life cycle African trypanosomiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 611px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a blood meal on the mammalian host, an infected tsetse fly (genus",
"    <em>",
"     Glossina",
"    </em>",
"    ) injects metacyclic trypomastigotes into skin tissue. The parasites enter the lymphatic system and pass into the bloodstream",
"    <strong>",
"     (1)",
"    </strong>",
"    . Inside the host, they transform into bloodstream trypomastigotes",
"    <strong>",
"     (2)",
"    </strong>",
"    , are carried to other sites throughout the body, reach other blood fluids (eg, lymph, spinal fluid), and continue the replication by binary fission",
"    <strong>",
"     (3)",
"    </strong>",
"    . The entire life cycle of African Trypanosomes is represented by extracellular stages. The tsetse fly becomes infected with bloodstream trypomastigotes when taking a blood meal on an infected mammalian host",
"    <strong>",
"     (4,5)",
"    </strong>",
"    . In the fly's midgut, the parasites transform into procyclic trypomastigotes, multiply by binary fission",
"    <strong>",
"     (6)",
"    </strong>",
"    , leave the midgut, and transform into epimastigotes",
"    <strong>",
"     (7)",
"    </strong>",
"    . The epimastigotes reach the fly's salivary glands and continue multiplication by binary fission",
"    <strong>",
"     (8)",
"    </strong>",
"    . The cycle in the fly takes approximately three weeks. Humans are the main reservoir for",
"    <em>",
"     Trypanosoma brucei gambiense",
"    </em>",
"    , but this species can also be found in animals. Wild game animals are the main reservoir of",
"    <em>",
"     T. b. rhodesiense",
"    </em>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers of Disease Control and Prevention. Parasites and Health: Trypanosomiasis, African. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/TrypanosomiasisAfrican.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/TrypanosomiasisAfrican.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39224=[""].join("\n");
var outline_f38_19_39224=null;
var title_f38_19_39225="Mechanical complications of acute myocardial infarction";
var content_f38_19_39225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanical complications of acute myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39225/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39225/contributors\">",
"     Roger J Laham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39225/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39225/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39225/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39225/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/19/39225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major mechanical complications of acute myocardial infarction (MI): rupture of the left ventricular free wall; rupture of the interventricular septum; and the development of mitral regurgitation. One study compared 225 patients who had a first MI and experienced one of these complications to 1012 patients with a first MI without these mechanical complications&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/1\">",
"     1",
"    </a>",
"    ]. Delayed hospitalization (&ge;24 hours), undue in-hospital physical activity, and postinfarction angina increased the risk of rupture in predisposed patients.",
"   </p>",
"   <p>",
"    The clinical issues related to these mechanical problems, each of which can result in cardiogenic shock, will be reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on ST elevation MI and on CABG recommended emergent surgery, with coronary artery bypass grafting (CABG) if indicated, for these mechanical complications of an acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. No changes to this approach were made in the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    focused update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this topic MI will refer to ST elevation MI (STEMI), unless otherwise indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RUPTURE OF THE LEFT VENTRICULAR FREE WALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute or subacute myocardial rupture is a serious and often lethal complication of STEMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of the free wall of the infarcted ventricle is a relatively common finding in patients dying with an acute MI. Several large studies have found cardiac rupture in 14 to 26 percent of such patients (",
"    <a class=\"graphic graphic_picture graphicRef75582 \" href=\"mobipreview.htm?43/23/44405\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The incidence is much lower when all patients with acute MI are considered. As an example, the National Registry of Myocardial Infarction published data on 350,755 patients in 1996 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/8\">",
"     8",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of cardiac rupture was less than 1 percent; this is consistent with a 0.85 percent incidence of tamponade in a review of over 100,000 patients treated with fibrinolytic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24055?source=see_link&amp;anchor=H9#H9\">",
"       \"Pericardial complications of myocardial infarction\", section on 'Risk of tamponade'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac rupture was responsible for 7.3 percent of all deaths and for 12.1 percent among those receiving a fibrinolytic agent.",
"     </li>",
"     <li>",
"      Death from rupture occurred earlier among patients receiving a fibrinolytic agent, often within 24 hours of drug administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall incidence of free wall rupture was approximately four percent in a small, single center study which evaluated patients with STEMI in five year blocks between 1977 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence declined progressively from 1977 to 1982 (above four percent) to 2001 to 2006 (about two percent). This decline was associated with both a progressive fall in the rate of death (94 to 75 percent) and a progressive increase in the use of reperfusion therapies, better control of blood pressure, and the use of beta blockers and angiotensin-converting enzyme inhibitors and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although fibrinolytic therapy accelerates the occurrence of rupture, the TIMI 9 study of 3759 patients found no association between cardiac rupture and the use of adjunctive thrombin inhibitors, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and hirudin, or the intensity of systemic anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of cardiac rupture may be lower in patients treated with percutaneous coronary intervention compared to those receiving a fibrinolytic agent. This was suggested in an observational study of 1375 patients who received a fibrinolytic agent or underwent primary angioplasty, the incidence of rupture was 3.3 and 1.8 percent, respectively with the two therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/12\">",
"     12",
"    </a>",
"    ]. In a multivariate analysis, the use of angioplasty was a significant independent protective factor (odds ratio 0.46).",
"   </p>",
"   <p>",
"    Risk factors for myocardial rupture have been identified in addition to fibrinolytic therapy. The Multicenter Investigation of Limitation of Infarct Size (MILIS) study, for example, found that myocardial rupture was 9.2 times more likely to occur in patients with all of the following characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No history of previous angina or MI",
"     </li>",
"     <li>",
"      ST-segment elevation or Q wave development on the initial ECG",
"     </li>",
"     <li>",
"      Peak MB-creatine kinase above 150",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These associations suggest that the absence of collateral blood flow (suggested by the lack of previous ischemic symptoms) and the size of the infarct are important determinants of the likelihood of myocardial rupture. This hypothesis has been confirmed in other studies that have found that rupture is usually associated with a large transmural infarct, occurs more frequently in patients without previous MI, and is rarely seen in an hypertrophied ventricle or in an area of extensive collateral circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8216?source=see_link\">",
"     \"Coronary collateral circulation\"",
"    </a>",
"    .) In addition, affected patients often have persistent ST segment elevation and persistent or recurrent chest pain with evidence of infarct expansion or extension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other risk factors for rupture include anterior location of the infarction, age &gt;70, and female sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. On the other hand, beta blockers, which are routinely administered to patients with an acute MI, reduce the rate of death from free wall rupture compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial rupture occurs within the first five days after MI in about one-half of cases and within two weeks in over 90 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. A number of different pathologic patterns can be seen depending in part upon the time of occurrence (",
"    <a class=\"graphic graphic_figure graphicRef75673 \" href=\"mobipreview.htm?38/33/39447\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/17\">",
"     17",
"    </a>",
"    ]. This was illustrated by a study of 1450 consecutive patients with acute MI, 27 (1.9 percent) of whom developed free wall myocardial rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/21\">",
"     21",
"    </a>",
"    ]. The findings were different in early phase (&lt;72 hours) and late (&gt;4 days) ruptures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early rupture was characterized by an abrupt slit-like tear in the infarcted myocardium, with a preference for anterior infarction sites. There was no difference in incidence in between patients treated with conventional and reperfusion therapy.",
"     </li>",
"     <li>",
"      Late rupture was characterized by the presence of infarct expansion, with no preferential infarction site. There was a very low incidence in patients with successful reperfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myocardial rupture more frequently involves the left ventricle than the right ventricle, and rarely involves the atria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/8,20,22\">",
"     8,20,22",
"    </a>",
"    ]. The infarct commonly affects the anterior and lateral walls of the left ventricle near the junction of the infarcted and normal myocardium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect of reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial rupture after MI is less common in patients with a patent infarct-related coronary artery. Such an association was demonstrated in a retrospective review that evaluated the perfusion status of the infarct-related coronary artery in 57 patients who had an initially nonfatal rupture and 28 patients with a postmortem diagnosis of myocardial rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/23\">",
"     23",
"    </a>",
"    ]. Rupture typically occurred in an area that had been infarcted without successful reperfusion. A coronary angiogram was available in 35 of the 57 patients with initial nonfatal rupture. Complete occlusion or ineffective reperfusion was present in 30 (89 percent). In addition, all 28 patients with a postmortem diagnosis of rupture had inadequate reperfusion of the infarcted area.",
"   </p>",
"   <p>",
"    A number of studies have shown that fibrinolytic therapy early after MI improves survival and decreases the risk of cardiac rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The TIMI investigators examined the hearts of 61 patients who died from five hours to 42 days (median of three days) after a fatal first acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/25\">",
"     25",
"    </a>",
"    ]. In this selected group, myocardial rupture (of the left ventricular free wall or septum) was a relatively common complication. However, the frequency of myocardial rupture was lower in the 23 patients who received fibrinolytic therapy than in the 38 patients who did not (22 versus 46 percent). Percutaneous coronary intervention (PCI) may also reduce the risk of cardiac rupture if successful reperfusion is achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these general findings, fibrinolytic therapy may be associated with a significant increase in free wall rupture in patients &ge;75 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a review of 706 consecutive patients &ge;75 years of age with a first STEMI who were treated with primary PCI, fibrinolytic therapy, or no reperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/29\">",
"     29",
"    </a>",
"    ]. The patients who received fibrinolytic therapy had a significantly greater likelihood of free wall rupture (17.1 versus 7.9 and 4.9 percent in those with no reperfusion and primary PCI, respectively, adjusted relative risk 3.62 compared to no reperfusion). Free wall rupture accounted for 54 percent of deaths after fibrinolytic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Late reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue from the overall efficacy of reperfusion to reduce the incidence of free wall rupture is the value of late therapy. Initial suggestions that late administration of fibrinolytic therapy might increase the risk of cardiac rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] were disproved by the Late Assessment of Thrombolytic Efficacy (LATE) trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/26\">",
"     26",
"    </a>",
"    ]. In this study, 5711 patients were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    or placebo, six to 24 hours after the onset of symptoms. Late fibrinolysis did not increase the risk of cardiac rupture; it did, however, appear to accelerate the time of onset of rupture events, typically to within 24 hours of treatment.",
"   </p>",
"   <p>",
"    In contrast, late primary PCI may be associated with reductions in free wall rupture. These benefits were suggested in a retrospective review of 2209 patients with acute MI treated with primary PCI; clinical outcomes were analyzed after dividing the patients into three groups: early reperfusion (&le;12 hours after presentation), late reperfusion (&gt;12 hours after presentation, mean onset to admission time 17 hours), and failed reperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/31\">",
"     31",
"    </a>",
"    ]. The incidence of free wall rupture in those in the early and late reperfusion groups was significantly lower than for those with failed reperfusion (0.7 and 0.9 versus 3.8 percent).",
"   </p>",
"   <p>",
"    Late primary PCI (after 24 hours) of a totally occluded artery has not been shown to improve hard clinical outcomes however. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5930?source=see_link&amp;anchor=H26#H26\">",
"     \"Coronary artery patency and outcome after myocardial infarction\", section on 'Late PCI to open an occluded artery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of myocardial rupture is variable. Rupture can present as sudden death in an undetected or silent MI. With a known MI, complete or",
"    <span class=\"nowrap\">",
"     incomplete/subacute",
"    </span>",
"    rupture can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete rupture of the left ventricular free wall usually leads to hemopericardium and death from cardiac tamponade. The presence of rupture is first suggested by the development of sudden profound right heart failure and shock, often progressing rapidly to pulseless electrical activity (electromechanical dissociation) and death. Pulseless electrical activity in a patient with a first MI and without overt heart failure had, in one report, a high predictive accuracy (95 percent) for the diagnosis of left ventricular free wall rupture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/33\">",
"       33",
"      </a>",
"      ]. In contrast, the predictive accuracy of rupture was low (17 percent) in those with heart failure. Emergent pericardiocentesis will confirm the diagnosis and transiently relieve the tamponade. Transthoracic echocardiography can further confirm the diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Incomplete/subacute",
"      </span>",
"      rupture of the left ventricular free wall can occur when organized thrombus and the pericardium seal the ventricular perforation. This condition can progress to frank rupture with cardiac tamponade and hemodynamic compromise, to formation of a false aneurysm walled off by pericardial tissue and communicating with the left ventricle through the perforation, or to formation of a left ventricular diverticulum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/18-20,34\">",
"       18-20,34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25673?source=see_link\">",
"       \"Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction\"",
"      </a>",
"      .)",
"      <span class=\"nowrap\">",
"       <br/>",
"       <br/>",
"       Incomplete/subacute",
"      </span>",
"      rupture may be manifested clinically by persistent or recurrent chest pain, particularly pericardial pain, nausea, restlessness and agitation, abrupt, transient hypotension,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      electrocardiographic features of localized or regional pericarditis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. Echocardiographic and hemodynamic indices of cardiac tamponade were present in 85 percent of patients in one series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/17\">",
"       17",
"      </a>",
"      ]. The diagnosis of",
"      <span class=\"nowrap\">",
"       incomplete/subacute",
"      </span>",
"      rupture is confirmed by transthoracic echocardiography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival depends primarily upon the rapid recognition of myocardial rupture and provision of immediate therapy. Patients displaying suggestive symptoms, signs, and ECG changes require a bedside echocardiogram and echocardiographically-guided pericardiocentesis if fluid is visualized. Immediate surgery is indicated if the pericardiocentesis identifies the fluid as blood. Medical therapy aimed at hemodynamic stabilization should also be instituted. This includes fluids, inotropic support, vasopressors, pericardiocentesis, intraaortic-balloon pump counterpulsation, and percutaneous cardiopulmonary bypass (if available and necessary) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/15,18-21,24,26\">",
"     15,18-21,24,26",
"    </a>",
"    ]. Prompt surgical repair is also indicated for left ventricular false aneurysms because rupture of the pseudoaneurysm can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rapid institution of the above regimen can lead to an appreciable survival rate, particularly in subacute rupture. In one study, for example, 25 of 33 patients (76 percent) with subacute ventricular rupture survived the surgical procedure and 16 (48 percent) were long-term survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RUPTURE OF THE INTERVENTRICULAR SEPTUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of septal rupture has been reported to be about half that of free wall rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/10\">",
"     10",
"    </a>",
"    ]. It typically occurs three to five days after an acute MI. It may, however, develop within the first 24 hours or as late as two weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of septal rupture may observed in patients with single-vessel disease (especially the left anterior descending artery), extensive myocardial damage, and poor septal collateral circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. Septal rupture may also be seen in patients with multivessel coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/14,37\">",
"     14,37",
"    </a>",
"    ] and there is a higher prevalence in first infarctions.",
"   </p>",
"   <p>",
"    Due to the nature of the septal blood supply, patients with an MI due to occlusion of a \"wrap around\" left anterior descending (LAD) artery appear to have an elevated risk of septal rupture. In most individuals, the inferior one-third of the septum is supplied by the right coronary artery. In some individuals, however, the LAD extends beyond the left ventricular apex, wrapping around to supply the distal inferior wall and inferior septum.",
"   </p>",
"   <p>",
"    In patients with a \"wrap around\" LAD, an anterior MI due to LAD occlusion can result in more extensive septal infarction and reduced collateral supply to the septum, producing an increased risk of septal rupture and ST elevation in the inferior leads [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In contrast, patients with a high lateral wall MI are more likely to have reciprocal ST depression in the inferior leads, while other patients have no inferior ST segment changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, ECG evidence of infarction with a wrap around LAD (inferior ST elevation during a large anterior MI) may identify patients at high risk. In a report comparing 21 patients with an anterior MI and septal rupture to 275 similar patients without septal rupture, the patients with septal rupture were much more likely to have ST segment elevations (43 versus 4 percent) and Q waves (44 versus 4 percent) in all three inferior leads (II, III, and aVF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This series enrolled patients over a 27 year period; as a result, angiography confirming a wrap around LAD was not performed in all patients. ST elevation in a large number of leads predicts a larger infarction regardless of coronary anatomy, and such patients may be at increased of septal rupture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/26/4521?source=see_link&amp;anchor=H6#H6\">",
"     \"Electrocardiogram in the prognosis of myocardial infarction or unstable angina\", section on 'Extent of myocardial injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, because a number of these patients enrolled prior to the use of primary reperfusion therapies, the absolute risk of septal rupture in patients who present with extensive anterior and inferior ST elevations is probably overestimated in this series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect of reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the use of reperfusion, rupture of the interventricular septum occurred in about 2 percent of acute infarctions and accounted for approximately 10 percent of total cardiac ruptures (",
"    <a class=\"graphic graphic_picture graphicRef60314 \" href=\"mobipreview.htm?12/62/13285\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/5,35\">",
"     5,35",
"    </a>",
"    ]. The incidence of interventricular septal rupture in patients treated with fibrinolytic therapy is much lower than in patients treated conservatively. Among 41,021 patients in the GUSTO-I trial, for example, 0.2 percent developed a ventricular septal defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that, in patients who do develop interventricular septal rupture after acute MI, fibrinolytic therapy may lead to earlier breakdown of the interventricular septum and therefore earlier rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/43\">",
"     43",
"    </a>",
"    ]. In the GUSTO-I trial, the median time from symptoms to the development of an interventricular septal rupture was one day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Site of rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septal rupture is seen with equal frequency in anterior and non-anterior infarctions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/18\">",
"     18",
"    </a>",
"    ]. With anterior MI, the defect is most commonly found in the apical septum, and with inferior MI, it most often occurs at the base of the heart.",
"   </p>",
"   <p>",
"    Rupture develops at the margin of the necrotic and non-necrotic myocardium. The perforation is usually single and ranges from one to several centimeters in size. It may be a direct through-and-through hole or more irregular and serpiginous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/14,43\">",
"     14,43",
"    </a>",
"    ]. The size of the defect determines the magnitude of left-to-right shunting, which in turn affects the likelihood of survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a ruptured septum usually present with the precipitous onset of hemodynamic compromise characterized by hypotension, biventricular failure (often predominantly right-sided failure), and a new murmur. The murmur is harsh, loud, and holosystolic, and is heard best at the lower left and usually right sternal borders, with occasionally widespread radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/5,14,44\">",
"     5,14,44",
"    </a>",
"    ]. In some cases, the murmur is heard best at the apex and may be mistaken for acute mitral regurgitation. A thrill can be detected in up to 50 percent of patients; right ventricular lift and a hyperdynamic precordium may also be noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/14,44\">",
"     14,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who are not effectively reperfused, septal rupture is often associated (15 of 17 in one series) with persistent ST segment elevation for more than 72 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/45\">",
"     45",
"    </a>",
"    ]. The risk of septal rupture is increased in patients with right ventricular infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/43,45\">",
"     43,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of the diagnosis usually requires insertion of a pulmonary artery balloon catheter to document the left-to-right shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/5,14\">",
"     5,14",
"    </a>",
"    ]. Occasionally, giant pulmonary capillary wedge pressure V waves occur because of severe volume overload in the setting of reduced atrial and ventricular compliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The defect can also be diagnosed by two-dimensional transthoracic echocardiography with color flow Doppler imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/5,14,47-49\">",
"     5,14,47-49",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_movie graphicRef69435 \" href=\"mobipreview.htm?42/34/43554\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef57251 \" href=\"mobipreview.htm?17/39/18047\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef57768 \" href=\"mobipreview.htm?3/6/3171\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef54225 \" href=\"mobipreview.htm?33/50/34607\">",
"     movie 4",
"    </a>",
"    ). One study, for example, evaluated 43 patients with a post-MI ventricular septal defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/48\">",
"     48",
"    </a>",
"    ]. Two-dimensional echocardiography alone visualized the defect in only 17 (40 percent) of the patients. However, the addition of Doppler color flow mapping demonstrated both an area of turbulent transseptal flow and a diagnostic systolic flow disturbance within the right ventricular in all 43 patients. Transesophageal echocardiography may occasionally be necessary to delineate the complete extent of the abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of surgical repair in patients with post-MI ventricular septal rupture is controversial. Early retrospective studies noted lower operative mortality rates in patients who underwent surgery more than six weeks after infarction than in those who underwent earlier operation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. However, these observations reflected selection bias, in which patients with relatively well-preserved left ventricular function and smaller defects survived to become low risk surgical candidates.",
"   </p>",
"   <p>",
"    The optimal approach varies with the clinical presentation. In patients with cardiogenic shock, death is inevitable in the absence of urgent surgical intervention. Stabilization is attempted with vasodilators (which reduce afterload, thereby decreasing left ventricular pressure and the left to right shunt), inotropic agents (which may increase the cardiac output), diuretics, and intraaortic balloon pump counterpulsation (which has actions similar to vasodilators).",
"   </p>",
"   <p>",
"    This is followed by cardiac catheterization to define the coronary anatomy and then surgical repair. Operative mortality is high in this setting, but the late results in survivors are excellent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/42,52-54\">",
"     42,52-54",
"    </a>",
"    ]. In the GUSTO-I trial, for example, 84 patients (0.2 percent) developed a ventricular septal defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/42\">",
"     42",
"    </a>",
"    ]. Surgical repair was performed in 40 percent of these patients at a median of 3.5 days after the onset of infarction symptoms. Survival at 30 days (53 versus 6 percent) and one year (47 versus 3 percent) was significantly higher in those undergoing surgery compared to those treated medically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6505?source=see_link\">",
"     \"Coronary artery bypass graft surgery after acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed elective surgical repair is feasible in patients with heart failure without shock, but the potential for unpredictable and rapid deterioration is always present. Adverse outcomes being correlated with advanced age and a lengthy delay between septal rupture and operation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term survival is also increased by bypassing of associated coronary artery disease. One study evaluated the outcome of 75 patients who had undergone coronary angiography and then surgical repair of a post-MI ventricular septal defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/57\">",
"     57",
"    </a>",
"    ]. Thirty three patients who had serious proximal multivessel coronary disease and underwent complete revascularization in addition to repair of the ventricular septal defect were compared to 19 patients with a similar degree of coronary disease in whom only the septal defect was repaired. The actuarial survival was higher in the bypassed group at five (72 versus 48 percent) and 10 years (29 versus zero percent).",
"   </p>",
"   <p>",
"    Similar findings were noted in a report of 104 patients with a post-MI ventricular septal defect who underwent coronary angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/58\">",
"     58",
"    </a>",
"    ]. Multivessel coronary artery disease was present in 52 patients, 41 of whom had complete revascularization. Single vessel disease was present in 52 patients in whom revascularization was not performed. Although complete revascularization did not affect in-hospital mortality, it reduced the late mortality (17 versus 27 percent for incomplete revascularization). Determinants of late cardiac mortality were postoperative cardiac failure, incomplete revascularization, and longer aortic cross clamp time.",
"   </p>",
"   <p>",
"    Transcatheter closure of a postinfarction ventricular septal defect is another potential approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/59\">",
"     59",
"    </a>",
"    ]. This technique may become a valuable tool in the acute treatment of septal rupture when other surgical treatments (such as bypass or valve replacement) are not indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ACUTE MITRAL REGURGITATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of mitral regurgitation (MR) after acute MI include ischemic papillary muscle displacement (previously known as papillary muscle dysfunction), left ventricular dilatation or true aneurysm, and papillary muscle or chordal rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/5,14,60-62\">",
"     5,14,60-62",
"    </a>",
"    ]. This discussion focuses on studies of patients who have had ST elevation MI, many of whom have more than mild MR.",
"   </p>",
"   <p>",
"    The spectrum of ischemic MR including chronic MR post MI, acute worsening of chronic MR, and MR in the setting of NSTEMI is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have described the frequency of MR during acute MI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report studied 1485 patients who underwent cardiac catheterization during an acute MI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/60\">",
"       60",
"      </a>",
"      ]. Mild 1+ to 2+ MR was noted in 215 patients (14 percent); this condition was typically transient during ischemia and was not associated with adverse events. In contrast, moderately severe to severe MR (3+ to 4+) was observed in 50 patients (3 percent) who had a mortality of 24 percent at 30 days and 52 percent at one year.",
"     </li>",
"     <li>",
"      In the SHOCK trial of early revascularization in cardiogenic shock after acute MI, 169 patients had echocardiograms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/63\">",
"       63",
"      </a>",
"      ]. Moderate or severe MR was seen in 39 percent; these patients had a significantly poorer survival at one year than those with mild or no MR (31 versus 58 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with moderate to severe MR (but without papillary muscle rupture) are hemodynamically stable. Many such patients improve with medical therapy and revascularization (by fibrinolysis or primary angioplasty); a minority will eventually require mitral valve repair or replacement with coronary artery bypass grafting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/60,64\">",
"     60,64",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_movie graphicRef54431 \" href=\"mobipreview.htm?33/59/34740\">",
"     movie 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef73594 \" href=\"mobipreview.htm?28/11/28850\">",
"     movie 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef62935 \" href=\"mobipreview.htm?28/52/29505\">",
"     movie 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef52748 \" href=\"mobipreview.htm?24/60/25539\">",
"     movie 8",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Silent MR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intensity of the murmur does not necessarily correlate with the severity of the murmur. Some patients with severe MR attributable to rupture have early equalization of left ventricular and left atrial pressures, resulting in silent MR or a relatively soft, short, and indistinct murmur in as many as 50 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/45/28376?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\", section on 'Silent MR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Papillary muscle rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary muscle rupture is a life-threatening complication of acute MI that accounts for approximately 5 percent of deaths in these patients (",
"    <a class=\"graphic graphic_picture graphicRef52175 \" href=\"mobipreview.htm?2/61/3026\">",
"     picture 3",
"    </a>",
"    ). It usually occurs two to seven days after the infarct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/60,64\">",
"     60,64",
"    </a>",
"    ]. The rupture may be partial (occurring at one of the muscle heads) or complete.",
"   </p>",
"   <p>",
"    Because of differences in blood supply, rupture of the posteromedial papillary muscle occurs six to 12 times more frequently than rupture of the anterolateral papillary muscle. The posteromedial papillary muscle is supplied with blood from the posterior descending artery, while the anterolateral papillary muscle has a dual blood supply from the left anterior descending and left circumflex arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/5,14,60,65\">",
"     5,14,60,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Papillary muscle rupture occurs in both ST elevation and non-ST elevation infarcts. Most patients have relatively",
"    <strong>",
"     small",
"    </strong>",
"    areas of necrosis with poor collaterals, and up to 50 percent have single vessel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/5,60\">",
"     5,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8216?source=see_link\">",
"     \"Coronary collateral circulation\"",
"    </a>",
"    .) An autopsy study of 22 patients with postinfarction papillary muscle rupture found that 82 percent occurred in patients with a first MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study compared 31 patients with papillary muscle rupture with 1012 patients without rupture following an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/67\">",
"     67",
"    </a>",
"    ]. The patients with papillary muscle rupture had a significantly higher frequency of prolonged admission delay beyond 24 hours (55 versus 8 percent of those without rupture) and of recurrent anginal pain before or during hospitalization (46 versus 12 percent), suggesting that postinfarction ischemia or infarct extension were contributing factors.",
"   </p>",
"   <p>",
"    The clinical manifestations of papillary muscle rupture include the acute onset of hypotension and pulmonary edema with a hyperactive precordium and a mid-, late-, or holosystolic murmur that may have widespread radiation. Although the murmur may be loud, a thrill is generally not present. Furthermore, as noted above, many patients have no or only a soft murmur.",
"   </p>",
"   <p>",
"    The pulmonary capillary pressure tracing usually shows giant V waves. However, this finding is nonspecific since it may also be associated with an acute ventricular septal defect and severe left-sided heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/60,68\">",
"     60,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of papillary muscle rupture or severe dysfunction is suggested by the combination of hemodynamic compromise and a new systolic murmur in the setting of an acute myocardial infarction. An echocardiographic study evaluating 50 such patients found that 43 had a VSD and 7 had papillary muscle rupture or severe dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of papillary muscle disease after MI is typically confirmed by echocardiography (with color flow Doppler) and cardiac catheterization is performed to define the coronary anatomy (",
"    <a class=\"graphic graphic_movie graphicRef73295 \" href=\"mobipreview.htm?27/19/27952\">",
"     movie 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef77752 \" href=\"mobipreview.htm?33/17/34065\">",
"     movie 10",
"    </a>",
"    ). Two-dimensional transthoracic echocardiography usually demonstrates a flail segment of the mitral valve, and a severed papillary muscle or chordae can frequently be seen moving freely within the left ventricular cavity. In some cases, however, transthoracic echocardiography is not informative and transesophageal echocardiography is required to establish the diagnosis; this is most likely to occur in those patients in whom the ruptured head does not prolapse into the left atrium (which may occur in up to 35 percent of cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/49\">",
"     49",
"    </a>",
"    ]. Left ventricular function is usually hyperdynamic as a result of ventricular contraction against the low impedance left atrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/5,60,66\">",
"     5,60,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt diagnosis and initiation of medical therapy and emergent surgery are all necessary for a favorable outcome. Medical therapy includes aggressive afterload reduction often using nitrates, sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , diuretics, and intraaortic balloon pump counterpulsation. Afterload reduction decreases the regurgitant fraction, thereby increasing forward flow.",
"   </p>",
"   <p>",
"    Emergent surgical intervention remains the treatment of choice for papillary muscle rupture. Even though there is a high operative mortality (20 to 25 percent), survival in medically treated patients is very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/69\">",
"     69",
"    </a>",
"    ]. Mitral valve repair rather than replacement should be attempted in centers experienced in performing this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/60,64\">",
"     60,64",
"    </a>",
"    ]. Valve repair can be performed only when there is no papillary muscle necrosis.",
"   </p>",
"   <p>",
"    Long-term results in one study of 22 patients revealed a perioperative mortality of 27 percent and a seven year actuarial survival for the survivors of surgery of 64 percent; the overall seven-year survival was 47 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39225/abstract/69\">",
"     69",
"    </a>",
"    ]. The only factor that improved both immediate- and long-term survival was the concomitant performance of coronary artery bypass grafting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/2/32803?source=see_link\">",
"       \"Patient information: What can go wrong after a heart attack? (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three life threatening mechanical complications of acute myocardial infarction (MI): rupture of the left ventricular free wall; rupture of the interventricular septum; and the development of severe mitral regurgitation. The diagnosis is markedly facilitated by a heightened index of suspicion. Thus, a new murmur or evidence of hypoperfusion or severe acute decompensated heart failure in the presence of preserved or relatively preserved left ventricular systolic function should raise the possibility of a mechanical complication.",
"   </p>",
"   <p>",
"    The diagnosis can often be made using two-dimensional transthoracic or transesophageal echocardiography. A pulmonary artery catheter may be an adjunctive diagnostic tool for patients with suspected rupture of the interventricular septum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since each of these can lead to cardiogenic shock and death, therapy is most helpful if initiated emergently. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early surgical intervention is the definitive treatment and should be considered when there is a reasonable likelihood of survival. Insertion of an intra-aortic balloon pump may support the patient prior to surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericardiocentesis, vasopressors, and volume loading may be of value in the patient with rupture of the left ventricular free wall and evidence of tamponade. Diuresis, vasodilators, and inotropic agents may help patients with rupture of the interventricular septum, while vasodilator therapy helps many patients with acute mitral regurgitation.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/1\">",
"      Figueras J, Cortadellas J, Calvo F, Soler-Soler J. Relevance of delayed hospital admission on development of cardiac rupture during acute myocardial infarction: study in 225 patients with free wall, septal or papillary muscle rupture. J Am Coll Cardiol 1998; 32:135.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/3\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/5\">",
"      Reeder GS. Identification and treatment of complications of myocardial infarction. Mayo Clin Proc 1995; 70:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/6\">",
"      Stevenson WG, Linssen GC, Havenith MG, et al. The spectrum of death after myocardial infarction: a necropsy study. Am Heart J 1989; 118:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/7\">",
"      Pohjola-Sintonen S, Muller JE, Stone PH, et al. Ventricular septal and free wall rupture complicating acute myocardial infarction: experience in the Multicenter Investigation of Limitation of Infarct Size. Am Heart J 1989; 117:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/8\">",
"      Becker RC, Gore JM, Lambrew C, et al. A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol 1996; 27:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/9\">",
"      Patel MR, Meine TJ, Lindblad L, et al. Cardiac tamponade in the fibrinolytic era: analysis of &gt;100,000 patients with ST-segment elevation myocardial infarction. Am Heart J 2006; 151:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/10\">",
"      Figueras J, Alcalde O, Barrab&eacute;s JA, et al. Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period. Circulation 2008; 118:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/11\">",
"      Becker RC, Hochman JS, Cannon CP, et al. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol 1999; 33:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/12\">",
"      Moreno R, L&oacute;pez-Send&oacute;n J, Garc&iacute;a E, et al. Primary angioplasty reduces the risk of left ventricular free wall rupture compared with thrombolysis in patients with acute myocardial infarction. J Am Coll Cardiol 2002; 39:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/13\">",
"      Mann JM, Roberts WC. Rupture of the left ventricular free wall during acute myocardial infarction: analysis of 138 necropsy patients and comparison with 50 necropsy patients with acute myocardial infarction without rupture. Am J Cardiol 1988; 62:847.",
"     </a>",
"    </li>",
"    <li>",
"     Pasternak RC, Braunwald E, Sobel BE. Acute myocardial infarction. In: Heart Disease, 4th ed, Braunwald EB (Ed), Saunders, Philadelphia 1992. p.200.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/15\">",
"      Figueras J, Cortadellas J, Soler-Soler J. Left ventricular free wall rupture: clinical presentation and management. Heart 2000; 83:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/16\">",
"      Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Lancet 1988; 1:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/17\">",
"      Purcaro A, Costantini C, Ciampani N, et al. Diagnostic criteria and management of subacute ventricular free wall rupture complicating acute myocardial infarction. Am J Cardiol 1997; 80:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/18\">",
"      Batts KP, Ackermann DM, Edwards WD. Postinfarction rupture of the left ventricular free wall: clinicopathologic correlates in 100 consecutive autopsy cases. Hum Pathol 1990; 21:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/19\">",
"      Oliva PB, Hammill SC, Edwards WD. Cardiac rupture, a clinically predictable complication of acute myocardial infarction: report of 70 cases with clinicopathologic correlations. J Am Coll Cardiol 1993; 22:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/20\">",
"      L&oacute;pez-Send&oacute;n J, Gonz&aacute;lez A, L&oacute;pez de S&aacute; E, et al. Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria. J Am Coll Cardiol 1992; 19:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/21\">",
"      Nakatsuchi Y, Minamino T, Fujii K, Negoro S. Clinicopathological characterization of cardiac free wall rupture in patients with acute myocardial infarction: difference between early and late phase rupture. Int J Cardiol 1994; 47:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/22\">",
"      Woldow AB, Mattleman SJ, Ablaza SG, Nakhjavan FK. Isolated rupture of the right ventricle in a patient with acute inferior wall MI. Chest 1990; 98:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/23\">",
"      Cheriex EC, de Swart H, Dijkman LW, et al. Myocardial rupture after myocardial infarction is related to the perfusion status of the infarct-related coronary artery. Am Heart J 1995; 129:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/24\">",
"      Honan MB, Harrell FE Jr, Reimer KA, et al. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol 1990; 16:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/25\">",
"      Gertz SD, Kragel AH, Kalan JM, et al. Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators. Am J Cardiol 1990; 66:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/26\">",
"      Becker RC, Charlesworth A, Wilcox RG, et al. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study. J Am Coll Cardiol 1995; 25:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/27\">",
"      Morishima I, Sone T, Mokuno S, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995; 130:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/28\">",
"      Keeley EC, de Lemos JA. Free wall rupture in the elderly: deleterious effect of fibrinolytic therapy on the ageing heart. Eur Heart J 2005; 26:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/29\">",
"      Bueno H, Mart&iacute;nez-Sell&eacute;s M, P&eacute;rez-David E, L&oacute;pez-Palop R. Effect of thrombolytic therapy on the risk of cardiac rupture and mortality in older patients with first acute myocardial infarction. Eur Heart J 2005; 26:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/30\">",
"      Maggioni AP, Maseri A, Fresco C, et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). N Engl J Med 1993; 329:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/31\">",
"      Nakatani D, Sato H, Kinjo K, et al. Effect of successful late reperfusion by primary coronary angioplasty on mechanical complications of acute myocardial infarction. Am J Cardiol 2003; 92:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/32\">",
"      McMullan MH, Maples MD, Kilgore TL Jr, Hindman SH. Surgical experience with left ventricular free wall rupture. Ann Thorac Surg 2001; 71:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/33\">",
"      Figueras J, Cur&oacute;s A, Cortadellas J, Soler-Soler J. Reliability of electromechanical dissociation in the diagnosis of left ventricular free wall rupture in acute myocardial infarction. Am Heart J 1996; 131:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/34\">",
"      Frances C, Romero A, Grady D. Left ventricular pseudoaneurysm. J Am Coll Cardiol 1998; 32:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/35\">",
"      Pierli C, Lisi G, Mezzacapo B. Subacute left ventricular free wall rupture. Surgical repair prompted by echocardiographic diagnosis. Chest 1991; 100:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/36\">",
"      Radford MJ, Johnson RA, Daggett WM Jr, et al. Ventricular septal rupture: a review of clinical and physiologic features and an analysis of survival. Circulation 1981; 64:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/37\">",
"      Skehan JD, Carey C, Norrell MS, et al. Patterns of coronary artery disease in post-infarction ventricular septal rupture. Br Heart J 1989; 62:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/38\">",
"      Pr&ecirc;tre R, Rickli H, Ye Q, et al. Frequency of collateral blood flow in the infarct-related coronary artery in rupture of the ventricular septum after acute myocardial infarction. Am J Cardiol 2000; 85:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/39\">",
"      Birnbaum Y, Wagner GS, Gates KB, et al. Clinical and electrocardiographic variables associated with increased risk of ventricular septal defect in acute anterior myocardial infarction. Am J Cardiol 2000; 86:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/40\">",
"      Hayashi T, Hirano Y, Takai H, et al. Usefulness of ST-segment elevation in the inferior leads in predicting ventricular septal rupture in patients with anterior wall acute myocardial infarction. Am J Cardiol 2005; 96:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/41\">",
"      Sasaki K, Yotsukura M, Sakata K, et al. Relation of ST-segment changes in inferior leads during anterior wall acute myocardial infarction to length and occlusion site of the left anterior descending coronary artery. Am J Cardiol 2001; 87:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/42\">",
"      Crenshaw BS, Granger CB, Birnbaum Y, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation 2000; 101:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/43\">",
"      Mann JM, Roberts WC. Acquired ventricular septal defect during acute myocardial infarction: analysis of 38 unoperated necropsy patients and comparison with 50 unoperated necropsy patients without rupture. Am J Cardiol 1988; 62:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/44\">",
"      Perloff JK, Talano JV, Ronan JA Jr. Noninvasive techniques in acute myocardial infarction. Prog Cardiovasc Dis 1971; 13:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/45\">",
"      Vargas-Barr&oacute;n J, Molina-Carri&oacute;n M, Romero-C&aacute;rdenas A, et al. Risk factors, echocardiographic patterns, and outcomes in patients with acute ventricular septal rupture during myocardial infarction. Am J Cardiol 2005; 95:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/46\">",
"      Drobac M, Schwartz L, Scully HE, Bentley-Taylor MM. Giant left atrial V-waves in post-myocardial infarction ventricular septal defect. Ann Thorac Surg 1979; 27:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/47\">",
"      Bishop HL, Gibson RS, Stamm RB, et al. Role of two-dimensional echocardiography in the evaluation of patients with ventricular septal rupture postmyocardial infarction. Am Heart J 1981; 102:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/48\">",
"      Smyllie JH, Sutherland GR, Geuskens R, et al. Doppler color flow mapping in the diagnosis of ventricular septal rupture and acute mitral regurgitation after myocardial infarction. J Am Coll Cardiol 1990; 15:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/49\">",
"      Moursi MH, Bhatnagar SK, Vilacosta I, et al. Transesophageal echocardiographic assessment of papillary muscle rupture. Circulation 1996; 94:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/50\">",
"      Giuliani ER, Danielson GK, Pluth JR, et al. Postinfarction ventricular septal rupture: surgical considerations and results. Circulation 1974; 49:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/51\">",
"      Daggett WM, Guyton RA, Mundth ED, et al. Surgery for post-myocardial infarct ventricular septal defect. Ann Surg 1977; 186:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/52\">",
"      Jones MT, Schofield PM, Dark JF, et al. Surgical repair of acquired ventricular septal defect. Determinants of early and late outcome. J Thorac Cardiovasc Surg 1987; 93:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/53\">",
"      Davies RH, Dawkins KD, Skillington PD, et al. Late functional results after surgical closure of acquired ventricular septal defect. J Thorac Cardiovasc Surg 1993; 106:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/54\">",
"      Lemery R, Smith HC, Giuliani ER, Gersh BJ. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. Am J Cardiol 1992; 70:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/55\">",
"      Nishimura RA, Schaff HV, Gersh BJ, et al. Early repair of mechanical complications after acute myocardial infarction. JAMA 1986; 256:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/56\">",
"      Litton TC, Sutton JP, Smith CW, et al. Surgical treatment of ventricular septal rupture complicating myocardial infarction. Am J Surg 1988; 155:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/57\">",
"      Muehrcke DD, Daggett WM Jr, Buckley MJ, et al. Postinfarct ventricular septal defect repair: effect of coronary artery bypass grafting. Ann Thorac Surg 1992; 54:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/58\">",
"      Cox FF, Plokker HW, Morshuis WJ, et al. Importance of coronary revascularization for late survival after postinfarction ventricular septal rupture. A reason to perform coronary angiography prior to surgery. Eur Heart J 1996; 17:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/59\">",
"      Benton JP, Barker KS. Transcatheter closure of ventricular septal defect: a nonsurgical approach to the care of the patient with acute ventricular septal rupture. Heart Lung 1992; 21:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/60\">",
"      Lavie CJ, Gersh BJ. Mechanical and electrical complications of acute myocardial infarction. Mayo Clin Proc 1990; 65:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/61\">",
"      Tcheng JE, Jackman JD Jr, Nelson CL, et al. Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. Ann Intern Med 1992; 117:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/62\">",
"      Levine RA, Schwammenthal E. Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts. Circulation 2005; 112:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/63\">",
"      Picard MH, Davidoff R, Sleeper LA, et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 2003; 107:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/64\">",
"      David TE. Techniques and results of mitral valve repair for ischemic mitral regurgitation. J Card Surg 1994; 9:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/65\">",
"      James TN. Anatomy of the coronary arteries in health and disease. Circulation 1965; 32:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/66\">",
"      Barbour DJ, Roberts WC. Rupture of a left ventricular papillary muscle during acute myocardial infarction: analysis of 22 necropsy patients. J Am Coll Cardiol 1986; 8:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/67\">",
"      Figueras J, Calvo F, Cortadellas J, Soler-Soler J. Comparison of patients with and without papillary muscle rupture during acute myocardial infarction. Am J Cardiol 1997; 80:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/68\">",
"      Nishimura RA, Shub C, Tajik AJ. Two dimensional echocardiographic diagnosis of partial papillary muscle rupture. Br Heart J 1982; 48:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39225/abstract/69\">",
"      Kishon Y, Oh JK, Schaff HV, et al. Mitral valve operation in postinfarction rupture of a papillary muscle: immediate results and long-term follow-up of 22 patients. Mayo Clin Proc 1992; 67:1023.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 63 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39225=[""].join("\n");
var outline_f38_19_39225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RUPTURE OF THE LEFT VENTRICULAR FREE WALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect of reperfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Late reperfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RUPTURE OF THE INTERVENTRICULAR SEPTUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect of reperfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Site of rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ACUTE MITRAL REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Silent MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Papillary muscle rupture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/63\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/63|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/33/39447\" title=\"figure 1\">",
"      Morphologic types of ventricular free wall rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/63|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/23/44405\" title=\"picture 1\">",
"      LV free wall rupture post MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/62/13285\" title=\"picture 2\">",
"      Septal rupture post MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/61/3026\" title=\"picture 3\">",
"      Papillary muscle rupture after MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/63|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?42/34/43554\" title=\"movie 1\">",
"      VSD after MI TEE with color Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?17/39/18047\" title=\"movie 2\">",
"      VSD small four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?3/6/3171\" title=\"movie 3\">",
"      VSD short axis color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?33/50/34607\" title=\"movie 4\">",
"      VSD in Tetrology of Fallot parasternal long axis echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?33/59/34740\" title=\"movie 5\">",
"      Echo MR post MI four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?28/11/28850\" title=\"movie 6\">",
"      Echo MR in MI apical long axis color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?28/52/29505\" title=\"movie 7\">",
"      MR post MI parasternal long axis echo with closeup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?24/60/25539\" title=\"movie 8\">",
"      Echo parasternal long axis post MI MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?27/19/27952\" title=\"movie 9\">",
"      Ruptured papillary muscle post MI 2-chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?33/17/34065\" title=\"movie 10\">",
"      Ruptured papillary muscle post myocardial infarction long axis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6505?source=related_link\">",
"      Coronary artery bypass graft surgery after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8216?source=related_link\">",
"      Coronary collateral circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/26/4521?source=related_link\">",
"      Electrocardiogram in the prognosis of myocardial infarction or unstable angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25673?source=related_link\">",
"      Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/45/28376?source=related_link\">",
"      Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/2/32803?source=related_link\">",
"      Patient information: What can go wrong after a heart attack? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24055?source=related_link\">",
"      Pericardial complications of myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_19_39226="Overview of dietary trace minerals";
var content_f38_19_39226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of dietary trace minerals",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39226/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39226/contributors\">",
"     Sassan Pazirandeh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39226/contributors\">",
"     David L Burns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39226/contributors\">",
"     Ian J Griffin, MB ChB",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39226/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39226/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/19/39226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/19/39226/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/19/39226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minerals form only 5 percent of the typical human diet but are essential for normal health and function. Macrominerals are defined as minerals that are required by adults in amounts greater than 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or make up less than 1 percent of total body weight. Trace elements (or trace minerals) are usually defined as minerals that are required in amounts between 1 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by adults or make up less than 0.01 percent of total body weight. Ultra-trace minerals generally are defined as minerals that are required in amounts less than 1",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Although the classification of mineral may be controversial and somewhat arbitrary, one outline is given in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef73583 \" href=\"mobipreview.htm?4/17/4380\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic review will discuss the physiological and biochemical functions, dietary requirements, and signs and symptoms of excess and deficiency for the essential trace minerals, including iron, zinc, copper, manganese, fluoride, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    . Iodine (an ultra-trace mineral) will also be discussed because of its global importance in iodine deficiency. Several of these minerals are considered in more depth elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39864?source=see_link\">",
"     \"Iodine deficiency disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=see_link\">",
"     \"Zinc deficiency and supplementation in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several systems have been used to describe nutritional requirements of a population. Dietary Reference Intakes (DRIs) were developed by the Food and Nutrition Board of the Institute of Medicine to guide nutrient intake in a variety of settings. Under this system, requirements can be expressed as a Recommended Dietary Allowance (RDA), which is defined as the dietary intake that is sufficient to meet the daily nutrient requirements of 97 percent of the individuals in a specific life stage group. If there is insufficient data to determine an RDA for a given nutrient, requirements can be expressed as an Adequate Intake (AI), which is an estimation of the nutrient intake necessary to maintain a healthy state. The upper limit (UL) is the maximum daily intake of a nutrient that is likely to pose no risk of adverse effects. Intake of nutrients far in excess of the RDA is considered to be \"pharmacologic\" dosing. Dietary guidelines, which incorporate the RDAs, are periodically updated as new information arises.",
"   </p>",
"   <p>",
"    The United States Department of Agriculture uses different nomenclature and age groupings, setting \"Daily Values\" to describe recommended intake for adults and children older than four years of age. What appears on food labels is the estimation of the amount of a nutrient provided based upon a 2000 calorie diet. Updated information can be found at the website of the Food and Nutrition Information Center of the United States Department of Agriculture (",
"    <a class=\"external\" href=\"file://www.nal.usda.gov/fnic/index.html\">",
"     www.nal.usda.gov/fnic/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These terms are described in greater detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28631?source=see_link\">",
"     \"Dietary history and recommended dietary intake in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHROMIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1957, a compound extracted from pork kidney was termed \"glucose tolerance factor\" because it corrected hyperglycemia in rats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/1\">",
"     1",
"    </a>",
"    ]. Glucose tolerance factor was ultimately found to be chromium (Cr).",
"   </p>",
"   <p>",
"    Cr is a transition element and exists in multiple ionic states. Dietary Cr is in the trivalent state. The more oxidized form Cr4+ is a toxic and hazardous substance. Cr occurs as a component of a metalloenzymes and functions as a coenzyme in various metabolic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dietary sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cr is found in various food products, including grains, cereals, fruits, vegetables, and processed meats, which have a higher Cr content than unprocessed meats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cr is absorbed predominantly in the small intestine and is transported in the circulation bound to albumin and transferrin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/4\">",
"     4",
"    </a>",
"    ]. The total body Cr concentration is the main homeostatic control of its gut absorption. Dietary bioavailability of Cr is very low and almost all of the ingested chromium is excreted via feces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/5\">",
"     5",
"    </a>",
"    ]. Urinary and biliary excretion are alternative yet limited routes for its metabolism.",
"   </p>",
"   <p>",
"    Other minerals influence absorption and cellular uptake of Cr. There is enhanced absorption of Cr in the setting of zinc and iron deficiency, suggesting that these minerals compete for intestinal absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/4\">",
"     4",
"    </a>",
"    ]. Other factors that interfere with Cr absorption include certain drugs such as antacids, which contain magnesium, calcium, or aluminum salts. Nonsteroidal antiinflammatory drugs that inhibit the production of prostaglandins also reduce Cr absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/6\">",
"     6",
"    </a>",
"    ]. Cr can be reduced by gastric acid to form insoluble salts that can precipitate and block its absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/7\">",
"     7",
"    </a>",
"    ]. Administration of vitamin C enhances the uptake of Cr [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cr deficiency is generally limited to hospitalized patients with increased catabolism and metabolic demands in the setting of malnutrition. Some of the first case reports of Cr deficiency were from patients receiving parenteral nutrition. In diabetic patients receiving chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    , human Cr deficiency has been associated with increased insulin requirements. Cr supplementation in these patients improved glucose tolerance and respiratory quotient, which indicates a preference for fat metabolism and reduced utilization of carbohydrates as an energy source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other patients at risk for Cr deficiency include patients with short bowel syndrome, burns, traumatic injuries, or those on parenteral nutrition without appropriate trace mineral supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association has been suggested between low Cr levels and impaired glucose tolerance and unfavorable lipid profiles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/10\">",
"     10",
"    </a>",
"    ]. Randomized trials on this subject are of fair quality and have conflicting results, but generally suggest that chromium supplementation improved glycemia among patients with diabetes, but not among those with normal glucose tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little evidence to support Cr supplementation in individuals without Cr deficiency. A popular interest has developed in Cr supplementation as a method for improving lean body mass and muscle building. However, multiple studies have shown no clinically important changes in lean body mass, total body fat, or weight loss as a result of Cr supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no reports of adverse effects of dietary Cr (trivalent Cr). Animal studies suggest that high doses of Cr are nontoxic, because of poor oral bioavailability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/15\">",
"     15",
"    </a>",
"    ]. However, airborne hexavalent Cr (VI) toxicity has been established as a work-related etiology of lung cancer in stainless steel workers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Pentavalent (Cr V) and hexavalent Cr (Cr VI), which are not usually found in the diet, are toxic and carcinogenic by the inhalation route of exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/18\">",
"     18",
"    </a>",
"    ]. Industrial exposure to Cr (V and VI) can result in toxicity manifested as contact dermatitis, skin ulcers, and bronchogenic cancers. Tannery workers handling wet hides may develop Cr toxicity with elevated serum and urinary Cr levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dietary reference intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adequate intake of Cr for adults is 20 to 35 mcg per day (",
"    <a class=\"graphic graphic_table graphicRef51953 \" href=\"mobipreview.htm?37/22/38241\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COPPER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two heritable diseases are caused by inborn errors of copper metabolism: Wilson's disease is a disorder of copper excretion and is characterized by signs and symptoms of copper toxicity, whereas Menkes disease is a disorder of copper uptake from the intestine and is characterized by signs and symptoms of copper deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Dietary sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variability in the copper content of food reflects the variability in the copper content of soil. Further variability is introduced by variations in manufacturing methods.",
"   </p>",
"   <p>",
"    In the Western diet, approximately 60 percent of dietary copper comes from vegetable products, with vegetables, grains, and pulses (leguminous seeds such as beans, peas, and lentils) each providing approximately 20 percent. A further 20 percent comes from meat, fish, and poultry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/21\">",
"     21",
"    </a>",
"    ]. The highest content of copper is found in liver (20 to 180",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    versus 1 to 2.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in white bread and 0.02 to 0.08",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in cow's milk). According to the Third National Health and Nutrition Survey, the average daily dietary copper intake for adults in the United States is 1 to 1.6 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/20\">",
"     20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Copper is found in high concentrations in liver, brain, and to a lesser degree, in kidney, heart, and pancreas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/22\">",
"     22",
"    </a>",
"    ]. The total copper content in the adult human body is estimated to be 50 to 120 mg. The newborn term infant contains approximately 12 mg copper. Breast milk contains relatively little copper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Early in lactation breast milk contains up to 0.7",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    copper but this rapidly falls to 0.2",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    and may provide less than the recommended copper intake by the WHO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/25\">",
"     25",
"    </a>",
"    ]. During this period, any shortfall in copper intake can be met by mobilizing liver copper stores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copper is absorbed in the proximal small intestine and stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The acidic environment in the stomach facilitates solubilization of copper by dissociating it from copper containing dietary macromolecules. Absorption occurs by a saturable active transport process at lower levels of dietary copper and by passive diffusion at high levels of dietary copper. The Menkes P-type ATPase (ATP7A) is responsible for copper trafficking to the secretory pathway for efflux from enterocytes and other cells. Absorbed copper is loosely bound to plasma albumin and amino acids in the portal blood and taken to the liver where most of it is taken up on the first pass.",
"   </p>",
"   <p>",
"    In the liver, the copper is incorporated into the copper-containing protein ceruloplasmin, which serves to transport copper from the liver to peripheral tissues. Ceruloplasmin binds to its receptors on the cell surface; copper is then released from its binding protein and enters the cell. Ceruloplasmin has an independent role in iron metabolism, in which it serves as a plasma ferroxidase, converting iron to a valence that can be bound by plasma transferrin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Metallothionein, synthesized in the liver, may act as a copper storage protein.",
"   </p>",
"   <p>",
"    Approximately 50 percent of copper is excreted in the bile while the remaining half is excreted through other gastrointestinal secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This excretion of copper into the gastrointestinal tract is the major pathway that regulates copper homeostasis and prevents deficiency or toxicity. The Wilson P-type ATPase (ATP7B) is responsible for copper trafficking to the secretory pathway for ceruloplasmin biosynthesis and for endosome formation prior to biliary secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Biological role",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of important copper-containing enzymes have been described, including the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Zinc-copper superoxide dismutase (antioxidant defense); dopamine mono-oxygenase (neurotransmitter synthesis)",
"     </li>",
"     <li>",
"      Lysyl oxidase (collagen cross-linking, bone formation)",
"     </li>",
"     <li>",
"      Ceruloplasmin (copper transporter and ferroxidase)",
"     </li>",
"     <li>",
"      Cytochrome c oxidase (electron transport)",
"     </li>",
"     <li>",
"      Factor V (thrombosis)",
"     </li>",
"     <li>",
"      Tyrosinase (melatonin production)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These cupro-enzymes help to explain some of the clinical features of severe copper deficiency, including lack of skin pigmentation (decreased dopamine beta-hydrolase), weakness (decreased cytochrome c), and bleeding disorders (decreased factor V).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copper deficiency is characterized clinically by fragile, abnormally-formed hair, depigmentation of the skin, muscle weakness (myeloneuropathy), neurological abnormalities, edema, and hepatosplenomegaly, and osteoporosis. The neurologic manifestations include ataxia, neuropathy, and cognitive deficits that can mimic vitamin B12 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\", section on 'Copper deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11880?source=see_link\">",
"     \"Copper deficiency myeloneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hematologic features of copper deficiency include anemia (usually microcytic) and neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. Because the anemia is microcytic and hypochromic, it can be mistaken for the anemia of iron deficiency. If iron supplements are given, these can worsen copper deficiency because excess iron competes with copper and decreases net copper absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/40\">",
"     40",
"    </a>",
"    ]. Thrombocytopenia also may occur but is relatively rare. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\", section on 'Copper deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other laboratory findings include low plasma copper, ceruloplasmin, erythrocyte copper-zinc superoxide levels, and diminished 24-hour urinary copper excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment for copper deficiency consists of supplementation, and correction of the underlying cause of the deficiency, if possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\", section on 'Copper deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11880?source=see_link&amp;anchor=H37837827#H37837827\">",
"     \"Copper deficiency myeloneuropathy\", section on 'Treatment'",
"    </a>",
"    .) Patients on long-term total parenteral nutrition (TPN) require intravenous copper supplementation, which is usually provided as part of a mixture of trace metals. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Though rare, acquired copper deficiency has been well documented in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/22,32,41\">",
"     22,32,41",
"    </a>",
"    ]. Acquired copper deficiency in humans is associated with each of the following risk factors, which may be additive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foregut surgery, including gastrectomy or gastric bypass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/42-45\">",
"       42-45",
"      </a>",
"      ]. Copper deficiency should be considered in patients with a history of malabsorptive gastrointestinal surgery and myelopathy or new neurologic symptoms, which may mimic vitamin B12 deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/45\">",
"       45",
"      </a>",
"      ]. This is the most common cause of acquired copper deficiency and likely to become even more prominent as the rates of bariatric surgery increase. Typically, neurologic manifestations are delayed by years following gastric surgery.",
"     </li>",
"     <li>",
"      Premature infants receiving milk formulas without adequate copper supplementation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic diarrhea or other malabsorptive conditions including celiac disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/32,41,48,49\">",
"       32,41,48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic peritoneal dialysis or hemodialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Excessive zinc ingestion. Because copper and zinc are competitively absorbed from the jejunum via metallothionein, high doses of zinc can result in copper deficiency in normal individuals, particularly if combined with other risk factors such as gastric surgery. Excessive zinc has been ingested due to prolonged use of zinc supplements (eg, for common colds, acrodermatitis enteropathica, or other conditions) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/35,51\">",
"       35,51",
"      </a>",
"      ], ingestion of denture cream [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/52,53\">",
"       52,53",
"      </a>",
"      ], or from swallowing zinc-containing coins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/54\">",
"       54",
"      </a>",
"      ]. Parenteral zinc overloading during chronic hemodialysis has also been associated with copper deficiency myelopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment of Wilson&rsquo;s disease with chelation and zinc administration has occasionally caused iatrogenic copper deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment with the copper chelator Clioquinol (which was commonly used as an over the counter antiparasitic agent in Japan in the past) resulted in over 10,000 cases of myelo-optico-neuropathy in Japan in the 1960s, which may have been due to copper deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/57-59\">",
"       57-59",
"      </a>",
"      ]. Similarly, self-treatment with tetrathiomolybdate has been reported to cause copper deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to 1979, formulas for TPN did not include the addition of trace elements. As a result, those on chronic TPN often developed deficiencies in copper and other elements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/46\">",
"     46",
"    </a>",
"    ]. Free amino acids in parenteral nutrition also increase the urinary losses of copper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/61\">",
"     61",
"    </a>",
"    ]. Trace elements in TPN are sometimes withheld in the setting of cholestasis, and resulting copper deficiency in this setting has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Menkes disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menkes disease, also known as Menkes kinky hair syndrome, is a congenital x-linked genetic disorder with an incidence of about 1:100,000 live births. It is caused by a mutation of the transport protein mediating copper uptake from the intestine, encoded by the ATP7A gene. Inactivating mutations in this gene result in severe copper deficiency with progressive neurologic deterioration and death during early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. This gene is closely related to the gene responsible for copper overload in Wilson's disease, as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=see_link&amp;anchor=H3906210#H3906210\">",
"     \"Epidemiology and pathogenesis of Wilson disease\", section on 'Genetic defect in Wilson disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of Menkes disease are those of copper deficiency, but are severe and occur during early infancy. Affected individuals present with developmental delay, which usually becomes apparent during early infancy, and develop progressive neurologic symptoms. Physical features include peculiar \"kinky\" hair, growth retardation, hypopigmentation of the skin, and bony abnormalities, including osteoporosis and spur formation. The severity of the symptoms and lifespan are variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/65\">",
"     65",
"    </a>",
"    ]. Treatment consists of parenteral administration of a copper-histidine complex, which is not consistently effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute copper poisoning in humans causes gastrointestinal symptoms, including abdominal pain, diarrhea, and vomiting. In more severe forms, it leads to cardiac and renal failure, hepatic necrosis, encephalopathy, and ultimately death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/66\">",
"     66",
"    </a>",
"    ]. It can result from accidental consumption by children, contaminated water sources, suicide attempts, and topical creams for burn treatment which contain copper salts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ceruloplasmin (like ferritin) is an acute phase reactant, so serum copper and ceruloplasmin levels are increased in inflammatory processes, pregnancy, coronary artery disease, diabetes, malignancies, and renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Wilson's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wilson's disease is an autosomal recessive disorder characterized by excessive copper accumulation and is caused by a mutation in a copper-ATPase enzyme closely related to the Menkes disease gene product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Excessive copper is deposited in many tissues and leads to cardiac dysfunction, liver cirrhosis, pancreatic dysfunction (diabetes mellitus), and neurological abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment for Wilson's disease consists of avoidance of high copper foods and copper chelation. In early stages, pharmacological doses of zinc may be effective in delaying the onset of symptomatic disease, because zinc competes with copper for absorption in the gastrointestinal tract. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/11/23737?source=see_link\">",
"     \"Treatment of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dietary reference intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RDA for copper is 340 mcg daily for young children and rises to 900 mcg daily for adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/20\">",
"     20",
"    </a>",
"    ]. The UL is 1000 mcg daily in young children and 10,000 mcg daily for adults (",
"    <a class=\"graphic graphic_table graphicRef51953 \" href=\"mobipreview.htm?37/22/38241\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FLUORIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoride is relatively common in the earth's crust, but its concentration in water (a major dietary source) is very variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/71\">",
"     71",
"    </a>",
"    ]. It has an important role in preventing dental caries, and is considered beneficial rather than essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dietary sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ground water contains fluoride in amounts between 0 and 40",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/71\">",
"     71",
"    </a>",
"    ]. The variability in water content explains much of the variability in total fluoride intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/73\">",
"     73",
"    </a>",
"    ]. There is a well described inverse relationship between fluoride intake and dental caries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/73\">",
"     73",
"    </a>",
"    ]. Many domestic water supplies are fluoridated in order to reduce the incidence of caries, although the practice has raised controversy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other important sources of fluoride are tea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/72\">",
"     72",
"    </a>",
"    ], seafood that contains edible bones or shells (eg, canned sardines) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/73\">",
"     73",
"    </a>",
"    ], medicinal supplements, and fluoridated toothpastes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary fluoride is absorbed rapidly in the stomach and small intestine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/71\">",
"     71",
"    </a>",
"    ]. One-quarter to one-third of the absorbed fluoride is taken up into calcified tissues, whereas the rest is lost in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/71\">",
"     71",
"    </a>",
"    ]. In bone and teeth, fluoride can displace hydroxyl ions from hydroxyapatite to produce fluorapatite or fluorohydroxyapatite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/71\">",
"     71",
"    </a>",
"    ]. About 99 percent of total body fluoride is contained in bones and teeth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/73\">",
"     73",
"    </a>",
"    ], and the amount steadily increases during life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Biological role",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains unclear whether fluoride is truly essential, although fluoride may have some beneficial effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/72\">",
"     72",
"    </a>",
"    ]. Animal models, such as rodents fed fluoride-deficient diets, have failed to show consistent findings of deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/72\">",
"     72",
"    </a>",
"    ]. However, once taken up into bone, fluoride appears to increase osteoblast activity and bone density, especially in the lumbar spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/75\">",
"     75",
"    </a>",
"    ]. Fluoride has been suggested as a therapy for osteoporosis since the 1960s, but despite producing denser bone, fracture risk is not reduced. Indeed, there is some evidence that nonvertebral fractures may be increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/73,76\">",
"     73,76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Fluoride'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only known association with low fluoride intake is the risk of dental caries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/77\">",
"     77",
"    </a>",
"    ], although the mechanism remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/78\">",
"     78",
"    </a>",
"    ]. The American Dental Association believes that one-half of the population of the US receives too little fluoride in their drinking water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/74\">",
"     74",
"    </a>",
"    ]; however, strong contradictory opinions also are held [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoride toxicity usually results from ingestion of high amounts of fluoride, either in water, fluoride supplements, or as fluorine-containing insecticides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/71,80\">",
"     71,80",
"    </a>",
"    ]. In industrial settings, toxicity also can occur by inhalation or by absorption through the skin (eg, hydrofluoric acid spills) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute toxicity is characterized by nonspecific gastrointestinal disturbances such as pain, nausea, vomiting, and diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/73\">",
"     73",
"    </a>",
"    ]. In severe cases, this may progress to renal and cardiac dysfunction, coma, and ultimately death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/73\">",
"     73",
"    </a>",
"    ]. In children, as little as 8.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    may produce symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic fluoride toxicity is usually caused by high fluoride concentrations in drinking water or the use of fluoride supplements. Chronic ingestion of high doses leads to dental fluorosis, a cosmetic disorder where the teeth become mottled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/71\">",
"     71",
"    </a>",
"    ]. In more severe cases, it leads to skeletal fluorosis, in which bone is radiologically dense, but fragile. Fractures can occur, and there may be calcification of ligaments and tendons, leading to reduced joint mobility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33192?source=see_link&amp;anchor=H13#H13\">",
"     \"Preventive dental care and counseling for infants and young children\", section on 'Fluoride'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Dietary reference intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended intake for fluoride is expressed as an adequate intake (AI) rather than RDA, because of the limited data available to determine the population needs. The AI for fluoride is 0.7 mg daily for toddlers, rising to 3 mg daily for adult women and 4 mg daily for adult men (",
"    <a class=\"graphic graphic_table graphicRef51953 \" href=\"mobipreview.htm?37/22/38241\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     IODINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dietary importance of iodine lies in the metabolism and homeostasis of the thyroid gland. Iodine is predominantly found in the thyroid gland where it is bound to tyrosine as monoiodothyronine (MIT), diiodothyronine (DIT), triiodothyronine (T3), and thyroxine (T4).",
"   </p>",
"   <p>",
"    Goiter, described as the enlargement of thyroid gland, was first associated with iodine deficiency in the early 1920s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/81\">",
"     81",
"    </a>",
"    ]. At that time, goiter was endemic in certain parts of the world and the Midwestern United States. In one study, administration of iodine treated and prevented goiter in children in goiter-endemic areas of Ohio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/82\">",
"     82",
"    </a>",
"    ]. Iodized salt was then introduced and led to reduction of hypothyroidism-related growth retardation and successful prevention of goiter.",
"   </p>",
"   <p>",
"    In the United States and other industrialized nations, iodine deficiency is rarely seen due to iodized water, salt, and bread. However, iodine deficiency still remains a major public health issue in parts of the world where its incorporation into diet has been unsuccessful, and iodine deficiency remains among the most common micronutrient deficiencies globally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. The epidemiology of iodine deficiency is described in greater detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39864?source=see_link\">",
"     \"Iodine deficiency disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Dietary sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine is heterogeneously distributed in the environment, with soil and water varying greatly in their iodine content. Iodine is found naturally in fish and seafood, as well as in drinking water and vegetables. Dairy products contain iodine because of iodine absorption from iodine-containing disinfectants. Some breads contain iodine from the dough oxidizers used in their manufacture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many countries, food staples such as table salt are fortified with iodine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/85\">",
"     85",
"    </a>",
"    ]. Up to 70 percent of the world's population has access to iodized table salt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingested iodine is absorbed readily in the proximal small bowel. Iodine in the circulation is taken up by the thyroid gland and any excess amount is filtered by the kidneys and excreted.",
"   </p>",
"   <p>",
"    Significant amounts of iodine are stored in the thyroid as the intermediate products of the thyroxine synthetic pathway and as the final hormones themselves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/84\">",
"     84",
"    </a>",
"    ]. Tri-iodotyrosine and thyroxine are secreted by the gland and have plasma half-lives of two and eight days, respectively. The principle excretory route for iodine is the urine; any losses into the gastrointestinal tract are rapidly reabsorbed. Urinary excretion of iodine, whether over 24 hours or normalized to urinary creatinine, can be used as a measure of iodine status or iodine intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=see_link\">",
"     \"Iodine-induced thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Biological role",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sole physiological role of iodine is to form a part of the two thyroid hormones: thyroxine (3,5,3',5'-tetraiodothyronine, T4) and tri-iodotyrosine (3,5,3'-tri-iodothyronine T3). The thyroid hormones have many physiological roles, including regulation of basal metabolic rate and gene regulation through specific thyroid response elements. In the setting of low iodine intake, adequate levels of iodotyrosines cannot be maintained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=see_link\">",
"     \"Iodine-induced thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine deficiency is associated with goiter, hypothyroidism, mental retardation, and increased neonatal and infant mortality. Levels of T4 and T3 are low and thyroid stimulating hormone (TSH) is high, due to loss of feedback inhibition on TSH synthesis. The increased TSH levels lead to hyperplasia and hypertrophy of the thyroid gland, with visible and palpable thyroid gland enlargement, known as goiter.",
"   </p>",
"   <p>",
"    The fetus is vulnerable to iodine deficiency (or any other cause of hypothyroidism) in the mother. Severe, irreversible mental retardation can result unless iodine deficiency is treated with supplements in the second trimester. Left untreated, cretinism develops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/84\">",
"     84",
"    </a>",
"    ]. The hallmark of this condition is severe mental retardation, with or without spasticity, umbilical hernia, and characteristic facial features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36585?source=see_link\">",
"     \"Neurologic manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sources of excess iodide include over-the-counter and prescription medications that may be ingested or applied to the skin or vaginal mucosa, radiographic contrast agents, and dietary supplements (kelp, seaweed).",
"   </p>",
"   <p>",
"    The normal thyroid gland is able to adapt to a wide range of iodine intake. The effects of excessive iodide in patients with abnormal thyroid glands differs from that in normal subjects, and depends upon the underlying disease process. As an example, in patients with endemic goiter and iodide deficiency, iodide administration may abruptly increase thyroid hormone production, causing hyperthyroidism. Conversely, in patients with Hashimoto's thyroiditis, iodide administration may induce or exacerbate hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=see_link\">",
"     \"Iodine-induced thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Dietary reference intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RDA for iodine is 90 mcg daily for children 1 to 8 years old, 120 mcg for children 9 to 13 years, and rises to 150 mcg daily for older adolescents and adults. During pregnancy and lactation, the RDA is 220 and 290 mcg daily, respectively (",
"    <a class=\"graphic graphic_table graphicRef51953 \" href=\"mobipreview.htm?37/22/38241\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     IRON",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of all the trace minerals, iron is the most widely known. Iron deficiency affects between 1 and 1.5 billion people worldwide, of whom 400 million also have iron deficiency anemia. Eighty percent of these people live in developing countries, where iron deficiency may account for 20 to 30 percent of infant and maternal mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Dietary sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary iron is present in two main forms. Heme iron is found in meat, poultry, and fish, where it typically comprises 40 percent of the total tissue iron. Its absorption is good and is relatively unaffected by underlying iron status. Typically, non-heme iron is found in vegetables and fruit, as well as iron-fortified food products. Absorption of non-heme iron increases as iron status declines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/87\">",
"     87",
"    </a>",
"    ]. Iron-fortified foods have become increasingly common in the Western diet, such that American children now consume more iron from cereal or breads than from beef or chicken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/88\">",
"     88",
"    </a>",
"    ]. Common dietary sources of iron are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef83735 \" href=\"mobipreview.htm?25/13/25822\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In developing countries, heme iron intake is very low and most dietary iron intake is from non-heme food sources. These foods, however, often have poor bioavailability of the non-heme iron because of the presence of phytate, which chelates iron and prevents its absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heme and non-heme iron are absorbed through different mechanisms. Although the mechanism of heme iron absorption remains poorly characterized, there is increasing knowledge about the molecular mechanisms of non-heme iron absorption, and of the central role of liver hepcidin in the regulation of iron absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/89\">",
"     89",
"    </a>",
"    ]. Heme iron is absorbed about twice as well as non-heme iron, and its absorption is unaffected by iron status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=see_link&amp;anchor=H21#H21\">",
"     \"Regulation of iron balance\", section on 'Intestinal iron absorption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-heme iron is absorbed throughout the small intestine, especially in the duodenum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/90\">",
"     90",
"    </a>",
"    ]. Absorption is increased by vitamin C and certain amino acids, and is inhibited by calcium, phytic acid, and tannates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once absorbed, iron is bound to a specific transport protein, transferrin, from which it is readily taken up by the bone marrow. Only trace amounts of non-transferrin bound iron are found in the plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/91\">",
"     91",
"    </a>",
"    ], usually chelated to amino acids or citrate. Non-transferrin bound iron is readily taken up by the liver, by evolutionarily primate mechanisms. The body has elaborate mechanisms to prevent \"free\" iron from being available to invading microorganisms or malignant cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/92\">",
"     92",
"    </a>",
"    ]. In addition, free iron can cycle between the Fe(2+) and Fe(3+) forms and produce potentially toxic free radicals by Fenton chemistry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=see_link\">",
"     \"Regulation of iron balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Iron toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iron losses from the body generally are very low (approximately 1",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    and occur in desquamated skin cells and occult blood loss in urine and feces. Menstruating women have additional iron losses of approximately 1 to 2",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The principle source of iron homeostasis is through changes in iron absorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=see_link&amp;anchor=H23#H23\">",
"     \"Regulation of iron balance\", section on 'Iron loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Biological role",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron's biological role arises from its reactivity, specifically the ability to cycle between the Fe(2+) and Fe(3+) forms. This cycling is also responsible for its potentially deleterious effect as a generator of free radicals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A typical adult male has a total body iron content of about 3 to 4 g, of which 75 percent is in the form of heme proteins. Most common is hemoglobin (the oxygen transport protein), but others include myoglobin (an oxygen storage protein in tissues), cytochrome c (electron transport), cytochrome P450, and peroxidases. Of total body iron, 20 to 30 percent is in the form of storage proteins such as ferritin and hemosiderin (a complex ferritin breakdown product). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=see_link&amp;anchor=H13#H13\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Normal body iron content'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less than 1 percent of iron is present as iron metalloenzymes, but these are critical in tyrosine, dopamine, serotonin, and noradrenaline synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/94\">",
"     94",
"    </a>",
"    ]. Other metalloenzymes include aldehyde oxidase, NADH dehydrogenase, tryptophan hydroxylase, succinic dehydrogenase, and xanthine oxidase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Iron is required as a cofactor by several enzymes, including phosphoenolpyruvate carboxykinase (the rate limiting step in gluconeogenesis), ribonucleotide reductase (DNA and RNA synthesis), and aconitase (a component of the tricarboxylic acid cycle).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most familiar feature of iron deficiency is a microcytic, hypochromic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/97\">",
"     97",
"    </a>",
"    ]. However, this is the extreme end of a spectrum of deficiency. Other features include lethargy and decreased work performance, which are not fully corrected by treatment of any associated anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4329?source=see_link\">",
"     \"Iron requirements and iron deficiency in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is increasing evidence that iron deficiency anemia in toddlers can lead to developmental delays which appear to be irreversible, even if iron therapy sufficient to correct the anemia is given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Iron deficiency anemia in the second year of life can produce development delays until at least 10 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/100\">",
"     100",
"    </a>",
"    ]. Maternal iron deficiency can triple the risk of delivering a low birth weight infant and double the risk of delivering a preterm infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/44/28362?source=see_link&amp;anchor=H16#H16\">",
"     \"Nutrition in pregnancy\", section on 'Iron'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The archetypal disease of iron overload is hereditary hemochromatosis. It is inherited in an autosomal recessive manner and affects 3:1000 Caucasians. It is characterized by iron overload, cardiomyopathy, cirrhosis of the liver, diabetes, and arthritis. The molecular basis of hereditary hemochromatosis has been identified. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iron overload states are associated with an increased risk of several malignancies (especially hepatocellular carcinoma). In addition, observational studies and one intervention trial suggest an association between iron stores and cancer risk even in the healthy population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42378?source=see_link&amp;anchor=H25#H25\">",
"     \"Cancer prevention\", section on 'Iron'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epidemiological studies suggest a possible link between increased iron stores and cardiovascular disease, even in individuals without hereditary iron overload syndromes, but data are conflicting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations of hereditary hemochromatosis\", section on 'Heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If confirmed, these findings suggest that maintaining low but adequate iron stores is an important health goal in developed countries. In developing countries, high iron status is rare and public health efforts generally focus on the prevention of iron deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     MANGANESE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manganese (Mn) was first shown to be essential for normal growth and development of rodents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/102\">",
"     102",
"    </a>",
"    ]. Its role in human health is still unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Dietary sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meat, fish, poultry, dried fruit, and nuts are good sources of manganese, but absorption is very variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/102\">",
"     102",
"    </a>",
"    ]. Tea also contains large amounts of manganese, but its bioavailability appears to be very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manganese is absorbed throughout the small intestine, but the coefficient of absorption generally is very low, possibly as low as 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. Manganese is converted from the Mn(2+) to the Mn(3+) form before being taken up by an active mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/103\">",
"     103",
"    </a>",
"    ]. Absorption is decreased following high dietary intakes or if total body manganese status is good [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/103\">",
"     103",
"    </a>",
"    ]. Absorption is inhibited by high dietary intakes of calcium, phosphate, and fiber [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/104\">",
"     104",
"    </a>",
"    ], and increased in the setting of iron deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following absorption, manganese is transported in the portal blood bound to albumin and alpha-2-macroglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. Once taken up by the liver, a proportion is rapidly excreted into the bile, while some enters mitochondrial, nuclear, or lysozymal pools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/104\">",
"     104",
"    </a>",
"    ]. It is not known how manganese is transported from the liver to peripheral tissues, but it may be bound to transferrin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/104\">",
"     104",
"    </a>",
"    ]. Approximately one-quarter of total body manganese is found in the bones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/104\">",
"     104",
"    </a>",
"    ]. Significant amounts also are found in tissues rich in mitochondria (liver, kidney, pancreas) and rich in melanin (retina, pigmented skin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excretion of manganese is primarily through bile into the gastrointestinal tract, and is lower during infancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Biological role",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manganese is found in manganese superoxide dismutase (Mn-SOD), arginase, glutamate synthetase, and pyruvate carboxylase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/104\">",
"     104",
"    </a>",
"    ]. Particular interest has been paid to Mn-SOD, which is important for detoxifying the superoxide radical to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/104\">",
"     104",
"    </a>",
"    ]. It also is found in other enzymes, where it may replace magnesium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies of manganese deficiency are in experimental animals, where it leads to poor growth, decreased fertility, ataxia, skeletal deformities, and abnormal fat and carbohydrate metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/20,107,108\">",
"     20,107,108",
"    </a>",
"    ]. In some animal models, the offspring of manganese-deficient mothers develop irreversible ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Manganese deficiency in humans is very unusual, but has been reported in individuals on a highly restricted diet. In experimental studies in humans, manganese deprivation was associated with a scaly dermatitis and dyslipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/109\">",
"     109",
"    </a>",
"    ]. One study suggested a possible link between low blood manganese levels and Perthes disease, but a second study in the same population failed to confirm the finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/110,111\">",
"     110,111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manganese toxicity (manganism) is a well recognized hazard in workers exposed to manganese aerosols or dust, as may occur in welding or steel industries; it has also been reported in individuals drinking well water with high concentrations of manganese [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. High levels of manganese can be neurotoxic, affecting primarily the extrapyramidal parts of the brain. Symptoms are similar to those of Parkinson's disease, and include dyscoordination, loss of balance, and confusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/104,114,115\">",
"     104,114,115",
"    </a>",
"    ]. Headache, vomiting, and hepatic dysfunction have also been reported.",
"   </p>",
"   <p>",
"    While only a small percentage of manganese is absorbed from food sources, almost all intravenously administered manganese is retained. This has raised concern for potential manganese toxicity from parenteral nutrition solutions containing manganese, which is a standard component of the trace element mixture commonly added to the solution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/116\">",
"     116",
"    </a>",
"    ]. Cases of probable manganese toxicity in children and adults on chronic parenteral nutrition have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/114,117\">",
"     114,117",
"    </a>",
"    ]. Intravenously fed neonates may be at risk, particularly if they have cholestasis which decreases manganese excretion. Current recommendations are that intravenous manganese be limited to less than 1",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    for neonates and children weighing up to 40 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. However, it is difficult to achieve this target while maintaining target intake for other trace minerals using available formulations of trace elements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biomarkers for manganese toxicity have not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/117,119\">",
"     117,119",
"    </a>",
"    ]. Elevations in serum and whole blood manganese concentrations are often found in individuals on chronic parenteral nutrition, and correlate with manganese-associated changes in signal intensity on brain MRI, but the association between these measurements and clinical symptoms has not been fully established.",
"   </p>",
"   <p>",
"    Manganese absorption is increased in the setting of iron deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/105\">",
"     105",
"    </a>",
"    ]. Manganese concentrations are increased by formula feeding (particularly soy formulas), biliary obstruction, or long-term parenteral nutrition. Whether the mild increases in serum manganese that occur in healthy infants as a result of formula feeding have any detectable effects on development has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Dietary reference intakes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended intake for manganese is expressed as an Adequate Intake (AI), because of the limited data available to determine the population needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/20\">",
"     20",
"    </a>",
"    ]. The tolerable upper limit for manganese is 2 mg daily in toddlers, and up to 11 mg daily for adults (",
"    <a class=\"graphic graphic_table graphicRef51953 \" href=\"mobipreview.htm?37/22/38241\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SELENIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     Selenium",
"    </a>",
"    (Se) is a trace mineral with a role in multiple biologic functions. Se deficiency was first identified in experiments in rats, which were made nutritionally deficient in vitamin E [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/121\">",
"     121",
"    </a>",
"    ]. The resulting liver injury could be prevented by Se supplementation.",
"   </p>",
"   <p>",
"    The optimal range for dietary intake of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    is narrow; potentially toxic intakes are closer to recommended dietary intakes than for other dietary trace minerals. Thus, supplementation may be beneficial for individuals with low selenium intake, but could be detrimental to those with normal or high selenium intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Dietary sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;In free-living animals and humans,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    is mostly in the form of two selenium-containing amino acids: seleno-cysteine and seleno-methionine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/123\">",
"     123",
"    </a>",
"    ]. Inorganic forms of selenium are used in supplements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seafood, kidney and liver, and meat are good sources of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/125\">",
"     125",
"    </a>",
"    ]. Drinking water usually contains very little selenium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/126\">",
"     126",
"    </a>",
"    ]. The selenium content of grains and seeds is variable and depends on the selenium content of the soil and the form in which selenium is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    has a high bioavailability (&gt;50 percent). Seleno-methionine is actively absorbed in the small intestine by the methionine absorptive pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. The absorptive route of seleno-cysteine is unknown. Inorganic selenium (in supplements) is passively absorbed in the duodenum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/124\">",
"     124",
"    </a>",
"    ]. Selenium absorption appears to be independent of the individual's selenium status and may be unregulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vivo,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    is a component of seleno-proteins. Seleno-methionine is incorporated into proteins in place of methionine and seems to serve as a storage pool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/124\">",
"     124",
"    </a>",
"    ]. Seleno-cysteine is the active form of selenium found in proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/124\">",
"     124",
"    </a>",
"    ]. It is absorbed directly from the diet, synthesized from seleno-methionine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/124\">",
"     124",
"    </a>",
"    ], or synthesized by direct replacement of an oxygen residue on serine while it is bound to a specific tRNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/123\">",
"     123",
"    </a>",
"    ]. Seleno-cysteine and seleno-methionine are catabolized to release selenium. The principal excretory route of selenium is the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Biological role",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 30 selenoproteins have been identified, of which the best known are the four forms of glutathione peroxidase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/127,128\">",
"     127,128",
"    </a>",
"    ], which are important in antioxidant defense, and iodo-thyronine deiodinase 2 (three forms), which serves as a catalyst for production of thyroid hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/125,129\">",
"     125,129",
"    </a>",
"    ]. Other seleno-proteins include seleno-protein P and seleno-protein synthetase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/127\">",
"     127",
"    </a>",
"    ]. Some have well defined roles, while others are still under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    deficiency is associated with skeletal muscle dysfunction and cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/129-131\">",
"     129-131",
"    </a>",
"    ] and may also cause mood disorders and impaired immune function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/132,133\">",
"     132,133",
"    </a>",
"    ], macrocytosis, and whitened nailbeds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h3\">",
"     Keshan disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keshan disease, an endemic cardiomyopathy that affects children and women of childbearing age in areas of China, has been linked to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/135\">",
"     135",
"    </a>",
"    ]. The geographical distribution of Keshan disease is associated with local diets, which are nearly devoid of selenium. The disorder responds to selenium supplements.",
"   </p>",
"   <p>",
"    An animal model of Keshan disease in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    deficient mice infected with Coxsackievirus has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/136\">",
"     136",
"    </a>",
"    ]. The mice have increased mutations in the viral genome, leading to a virus with greater cardiac virulence, causing a cardiomyopathy similar to that seen in Keshan disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h3\">",
"     Total parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trace elements (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/40/34435?source=see_link\">",
"     trace metals",
"    </a>",
"    ) added to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN) were historically not supplemented with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    . Several cases of selenium deficiency in chronic TPN users have been reported with cardiomyopathy and skeletal muscle dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/137\">",
"     137",
"    </a>",
"    ]. Selenium deficiency has been described in a child with lymphangiomatosis secondary to loss in chylous fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h3\">",
"     Other potential roles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other clinical effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    deficiency have been suggested, but are not well established:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune function &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       Selenium",
"      </a>",
"      is found in relatively high amounts in several tissues with hematopoietic and immune function potential, including liver, spleen, and lymph nodes. HIV replication is inhibited by selenium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/132\">",
"       132",
"      </a>",
"      ]. A number of studies have shown a linear relationship between selenium deficiency and a reduction in CD4 cell counts in HIV-infected patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/139\">",
"       139",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Impaired cell-mediated immunity has been demonstrated when tissue stores of selenium are depleted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/140\">",
"       140",
"      </a>",
"      ]. Natural killer cell activity is enhanced when selenium is supplemented in the diet of selenium depleted individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/141\">",
"       141",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thyroiditis &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       Selenium",
"      </a>",
"      supplementation may decrease inflammatory activity in patients with autoimmune thyroiditis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/142\">",
"       142",
"      </a>",
"      ], and may reduce the risk of postpartum thyroiditis in women who are positive for thyroid peroxidase (TPO) antibodies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/248?source=see_link\">",
"       \"Postpartum thyroiditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cancer &mdash; Epidemiologic studies support a possible relationship between Se and cancer mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/143,144\">",
"       143,144",
"      </a>",
"      ]. As a result, a number of studies have investigated the role of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      supplementation for prevention of cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42378?source=see_link&amp;anchor=H22#H22\">",
"       \"Cancer prevention\", section on 'Selenium'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link\">",
"       \"Risk factors for prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiovascular disease &mdash; As mentioned previously, glutathione peroxidase (GPx), a seleno-protein dependent enzyme, reduces",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      and other molecules with oxidative potential. In theory, the antioxidative effect protects lipid membranes, inhibits oxidative modification of low density lipoprotein, and suppresses platelet aggregation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/145\">",
"       145",
"      </a>",
"      ]. These effects would predict that Se supplementation should be protective of atherosclerotic disease. However, prospective and epidemiologic studies have shown mixed results, as discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link&amp;anchor=H7#H7\">",
"       \"Nutritional antioxidants in coronary heart disease\", section on 'Multivitamin supplements'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucose metabolism &mdash; Animal models suggest that low doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      may improve glucose metabolism, clinical studies in humans suggest that selenium supplementation does not confer benefit and may increase the risk of type 2 diabetes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9610?source=see_link\">",
"       \"Risk factors for type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    toxicity include nausea, emesis, diarrhea, hair loss, nail changes, mental status changes, and peripheral neuropathy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     Selenium",
"    </a>",
"    toxicity occurs with excess dietary intake, either through diets naturally high in selenium or \"megadose\" supplementation. In Enshi County, China, chronic consumption of nearly 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of selenium from a plant-based diet clinically resulted in hair and nail loss, tooth decay, dermatologic lesions, and neurologic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/146\">",
"     146",
"    </a>",
"    ]. Selenium toxicity occurred in 201 individuals in the United States who took a liquid dietary supplement containing 200 times the labeled content of selenium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/147\">",
"     147",
"    </a>",
"    ]. The median estimated dose of selenium consumed was over 41,000",
"    <span class=\"nowrap\">",
"     micrograms/day,",
"    </span>",
"    which is almost 800 times the recommended dietary allowance of 55",
"    <span class=\"nowrap\">",
"     micrograms/day,",
"    </span>",
"    and more than 100 times the tolerable upper intake limit of 400",
"    <span class=\"nowrap\">",
"     micrograms/day.",
"    </span>",
"    A previous outbreak of selenium poisoning occurred in 13 individuals who took a mislabeled supplement in 1983 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Dietary reference intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    is available from seafoods, organ meats, and plant foods. Plant Se content depends upon soil Se concentrations. The RDA for selenium is 20 mcg daily for young children, rising to 55 mcg daily for adults (",
"    <a class=\"graphic graphic_table graphicRef51953 \" href=\"mobipreview.htm?37/22/38241\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h1\">",
"     ZINC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zinc has been recognized as a distinct element since 1509, but was not identified as an essential mineral until the 1900s. In 1961, a link was established between zinc deficiency, endemic hypogonadism, and dwarfism in rural Iran [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/149-151\">",
"     149-151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In recent years much interest has been generated by the possibility that subclinical zinc deficiency may significantly increase the incidence of and morbidity and mortality from diarrhea and upper respiratory tract infections. Along with iron, iodine, and vitamin A, zinc deficiency is one of the most important micronutrient deficiencies globally. Several studies have now demonstrated that supplementation of high risk populations can have substantial health benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=see_link\">",
"     \"Zinc deficiency and supplementation in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Dietary sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meat and chicken are excellent sources of zinc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/152\">",
"     152",
"    </a>",
"    ], as are nuts and lentils. In the Western diet, food products such as breakfast cereal are fortified with zinc and these products provide an increasingly important source of zinc. Approximately 45 percent of adults may have inadequate zinc intakes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total body zinc averages 1.5 to 2.5 g in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/154\">",
"     154",
"    </a>",
"    ], similar to that of iron. A large proportion (60 percent) of total body zinc is in bone and muscle pools with slow turnover. Zinc is actively absorbed throughout the small intestine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/154,155\">",
"     154,155",
"    </a>",
"    ]. Typically, zinc absorption is 20 to 40 percent efficient, and may be related to zinc status.",
"   </p>",
"   <p>",
"    Zinc is absorbed mainly in the duodenum and jejunum, and to a lesser extent in the ileum and large intestine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/155,156\">",
"     155,156",
"    </a>",
"    ]. During digestion, dietary zinc is released and forms complexes with different ligands, namely amino acids, phosphates, organic acids, and histidines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/157\">",
"     157",
"    </a>",
"    ]. Zinc-ligand complexes are then absorbed through the intestinal mucosa by both an active and passive process. Once absorbed, the portal circulation carries zinc to the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is an intricate homeostatic control of zinc absorption, regulated by metallothionein, a metalloprotein that binds copper and other divalent cations. Metallothionein in the gut enterocyte is more avid for copper than zinc. This is advantageous for the treatment of Wilson's disease since regular intake of zinc will competitively block gut copper uptake. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/11/23737?source=see_link\">",
"     \"Treatment of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Zinc absorption may be impaired in pancreatic disease or insufficiency. Pancreatic enzymes are necessary for release of dietary zinc, and pancreatic juices may contain zinc-complexing ligands. Phytic acid is known to reduce zinc absorption. Zinc shares some common absorptive components with iron and copper, and the three minerals may compete for absorption. Zinc is transported bound to albumin. It is taken up by peripheral tissues and by the liver where it may be stored as metallothionein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major route of zinc excretion is via the gastrointestinal tract. Up to 10 percent of the circulating zinc is also excreted through urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/149\">",
"     149",
"    </a>",
"    ]. Zinc homeostasis is probably maintained by a combination of changes in fractional absorption and endogenous fecal zinc excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h2\">",
"     Biological role",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zinc owes its biological role to the ability to form tight bonds with certain amino acids, especially histidine and cysteine. When zinc binds four amino acids (tetradentate configuration), it serves a structural role maintaining protein structure (such as the beta-pleated sheet), and maintains nuclear stability and histone structure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/159\">",
"     159",
"    </a>",
"    ]. It is in this form that zinc contributes to zinc finger proteins that interact with DNA. When zinc binds three amino acids, the fourth site is temporarily taken by a water molecule; in this form, zinc can play a role in the metabolic activity of many proteins.",
"   </p>",
"   <p>",
"    Approximately 250 proteins contain zinc. These include enzymes such as angiotensin converting enzyme, alkaline phosphatase, carbonic anhydrase, DNA and RNA polymerases, copper-zinc superoxide dismutase, and metallothionein, as well as a large family of zinc proteins involved in gene transcription (such as the zinc finger proteins) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/160,161\">",
"     160,161",
"    </a>",
"    ]. Zinc has important roles both in cell division as well as apoptosis (programmed cell death).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild dietary zinc deficiency impairs growth velocity while severe depletion of zinc leads to growth retardation. Other clinical manifestations of zinc deficiency include delayed sexual maturation, impotence, hypogonadism, oligospermia, alopecia, dysgeusia (impaired taste), immune dysfunction, night blindness, impaired wound healing, and various skin lesions. The dermatologic changes occur primarily in the extremities or around body orifices and are often characterized by erythematous, vesiculobullous, and pustular lesions (",
"    <a class=\"graphic graphic_picture graphicRef59027 \" href=\"mobipreview.htm?4/3/4145\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/162\">",
"     162",
"    </a>",
"    ]. Other signs and symptoms of zinc deficiency include loss of taste, change in hair color, and easy pluckability of hair. Also seen but not specific are night blindness, impaired appetite, delayed wound healing, decubitus ulcers, and decreased sperm counts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=see_link\">",
"     \"Zinc deficiency and supplementation in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings such as these, suggesting zinc deficiency, have been described in chronic diseases such as malnutrition, malabsorption syndromes (such as chronic inflammatory bowel disease), prolonged breastfeeding, and following necrotizing enterocolitis in preterm infants. Reduced zinc absorption and stores have been demonstrated in patients who have undergone gastric bypass for obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/163\">",
"     163",
"    </a>",
"    ]. Pregnancy also increases the risk for zinc deficiency. Alcoholic cirrhotic patients often have low hepatic concentrations of zinc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/164\">",
"     164",
"    </a>",
"    ]. Cases of zinc deficiency have been reported among elderly individuals with poor diet quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/165\">",
"     165",
"    </a>",
"    ]. In these cases, the dietary zinc deficiency may have been exacerbated by medications that increase urinary losses of zinc, including thiazides, loop diuretics, and angiotensin receptor blockers. &nbsp;",
"   </p>",
"   <p>",
"    Zinc deficiency can be seen in patients receiving chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN) solutions lacking adequate zinc supplementation, or chronic TPN use with an underlying condition causing zinc losses, such as diarrhea, inflammatory bowel disease, or other conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/166\">",
"     166",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetics also have some alterations of zinc metabolism. Both type 1 and type 2 diabetics can exhibit hyperzincuria, which may have a role in the immune dysfunction associated with diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/167\">",
"     167",
"    </a>",
"    ]. Zinc supplementation in diabetic patients may improve immune function, but also increases the HbA1c levels and leads to worsening glucose intolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/168\">",
"     168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mild zinc deficiency appears to be common, especially in developing countries. Individuals in developing countries are at risk of zinc deficiency because the diet is relatively low in zinc and contain significant amounts of phytates (which reduce zinc absorption). There is some evidence supporting the role of zinc supplementation to increase growth velocity in children, and several studies have suggested a benefit of zinc supplementation in children with acute diarrhea in developing countries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=see_link\">",
"     \"Zinc deficiency and supplementation in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Zinc supplementation during pregnancy for women with mild zinc deficiency appears to promote fetal growth and reduce the risk of premature birth and infant diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/77,169-171\">",
"     77,169-171",
"    </a>",
"    ]. Zinc has also been used to treat the common cold, but probably has little clinical value. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=see_link\">",
"     \"The common cold in adults: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h3\">",
"     Acrodermatitis enteropathica",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acrodermatitis enteropathica (AE) is an autosomal recessive disease in which zinc absorption is impaired. The disorder is caused by mutations in the SLC39A4 gene on chromosome 8q24.3, which encodes a protein that appears to be involved in zinc transportation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/172,173\">",
"     172,173",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AE is characterized by signs and symptoms of severe zinc deficiency, including diarrhea, dermatitis (especially perioral and perianal), alopecia, poor growth, and poor immune function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/151\">",
"     151",
"    </a>",
"    ]. The dermatitis consists of hyperpigmented skin lesions on the acral surfaces of the upper and the lower extremities, as well as the face and buttocks (",
"    <a class=\"graphic graphic_picture graphicRef71329 \" href=\"mobipreview.htm?39/34/40481\">",
"     picture 2",
"    </a>",
"    ). Symptoms usually appear in early infancy, once breast-feeding is completely discontinued. Systemic signs include intestinal disturbances, growth failure, irritability, and lethargy. Thymic hypoplasia has also been described in association with AE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral supplementation with zinc (30 to 45 mg per day) leads to a rapid and complete remission of the symptoms. Therapy needs to be continued indefinitely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans are very tolerant of high zinc intakes up to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/174\">",
"     174",
"    </a>",
"    ]. Mega-dose supplementation or high zinc intake from contaminated food or beverages has been associated with nonspecific gastrointestinal symptoms, including abdominal pain, diarrhea, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/152,154,175\">",
"     152,154,175",
"    </a>",
"    ]. Zinc may interfere with copper absorption, and high zinc intakes (&gt;150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    can lead to copper deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/176\">",
"     176",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Copper'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment for zinc toxicity is primarily supportive, although chelation with calcium disodium ethylenediaminetetraacetate (CaNa2EDTA) has been used in some cases of severe toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h2\">",
"     Evaluation of zinc status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma levels of zinc do not necessarily correlate with tissue levels and do not reliably identify individuals with zinc deficiency. Although plasma levels are generally a good index of zinc status in healthy individuals, these levels are depressed during inflammatory disease states. Erythrocyte concentrations of zinc may provide a more useful measure of zinc status during acute or chronic inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/177\">",
"     177",
"    </a>",
"    ]. Several functional indices also can be used to indirectly assess zinc status. Serum superoxide dismutase and erythrocyte alkaline phosphatase activities have been proposed as indirect markers of zinc status, but these tests are not widely available.",
"   </p>",
"   <p>",
"    Because most zinc is bound to albumin, measured zinc levels may be reduced in patients with hypoalbuminemia. However, in clinical practice, it is not particularly helpful to correct measured zinc levels for hypoalbuminemia, because the correlation between zinc and albumin levels is weak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/178\">",
"     178",
"    </a>",
"    ] and plasma levels are loosely correlated with zinc stores. Moreover, zinc replacement is usually indicated for patients with low zinc levels, regardless of albumin status, depending upon the clinical context.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66\">",
"    <span class=\"h2\">",
"     Dietary reference intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Food and Nutrition Board of the Institute of Medicine and the World Health Organization (WHO) have published standard recommendations for daily zinc intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/19/39226/abstract/20,179\">",
"     20,179",
"    </a>",
"    ]. Requirements vary by age and gender, rising from 3 mg daily in early childhood to 8 mg daily for adult women, and 11 mg daily for adult men. Requirements are slightly higher during pregnancy and lactation (",
"    <a class=\"graphic graphic_table graphicRef51953 \" href=\"mobipreview.htm?37/22/38241\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minerals that are required in small amounts for human health are known as trace minerals or trace elements. These include zinc,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      , iodine, copper, chromium, manganese, fluoride, and molybdenum. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommended intakes for trace elements are expressed as Recommended Dietary Allowances (RDA) or Adequate Intake (AI). The Upper Limit (UL) is the quantity of the nutrient considered to cause no adverse effects in healthy individuals. These parameters have been estimated for each trace mineral (",
"      <a class=\"graphic graphic_table graphicRef51953 \" href=\"mobipreview.htm?37/22/38241\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Copper deficiency can be caused by an x-linked mutation of the transport protein mediating copper uptake from the intestine (Menkes disease). It can also be caused by malabsorption after gastrointestinal surgery (including gastric bypass for weight loss and gastric resection for malignancy or peptic ulcer disease), or by ingestion of high doses of zinc. Clinical manifestations include anemia, ataxia, and myeloneuropathy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Copper'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link&amp;anchor=H30#H30\">",
"       \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\", section on 'Copper deficiency'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11880?source=see_link\">",
"       \"Copper deficiency myeloneuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Iodine deficiency is characterized by goiter and hypothyroidism, which in turn has effects on growth, development, and cognitive function. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Iodine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       Selenium",
"      </a>",
"      deficiency is unusual, but has been reported in parts of China where the local diet is devoid of selenium; the deficiency also occurs in individuals maintained on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      without trace minerals. Clinical features of selenium deficiency are cardiomyopathy and skeletal muscle dysfunction. (See",
"      <a class=\"local\" href=\"#H48\">",
"       'Selenium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Zinc deficiency causes growth retardation in children, hypogonadism, oligospermia, alopecia, dysgeusia (impaired taste), immune dysfunction, night blindness, impaired wound healing, and skin lesions. Infants with an inherited defect in zinc absorption develop a severe deficiency state known as acrodermatitis enteropathica. (See",
"      <a class=\"local\" href=\"#H58\">",
"       'Zinc'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=see_link\">",
"       \"Zinc deficiency and supplementation in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/1\">",
"      SCHWARZ K, MERTZ W. A glucose tolerance factor and its differentiation from factor 3. Arch Biochem Biophys 1957; 72:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/2\">",
"      Mertz W. Chromium in human nutrition: a review. J Nutr 1993; 123:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/3\">",
"      Hardwick LL, Jones MR, Brautbar N, Lee DB. Magnesium absorption: mechanisms and the influence of vitamin D, calcium and phosphate. J Nutr 1991; 121:13.",
"     </a>",
"    </li>",
"    <li>",
"     Offenbacher EG, Pi-Sunyer FX, Stoecker BJ. Chromium. In: Handbook of nutritionally essential mineral elements, O'Dell BL, Sunde RA (Eds), Marcel Dekker, New York 1997. p.389.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/5\">",
"      Offenbacher EG, Spencer H, Dowling HJ, Pi-Sunyer FX. Metabolic chromium balances in men. Am J Clin Nutr 1986; 44:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/6\">",
"      Kamath SM, Stoecker BJ, Davis-Whitenack ML, et al. Absorption, retention and urinary excretion of chromium-51 in rats pretreated with indomethacin and dosed with dimethylprostaglandin E2, misoprostol or prostacyclin. J Nutr 1997; 127:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/7\">",
"      Mertz W. Chromium occurrence and function in biological systems. Physiol Rev 1969; 49:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/8\">",
"      Jeejeebhoy KN, Chu RC, Marliss EB, et al. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 1977; 30:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/9\">",
"      Nielsen FH. Nutritional significance of the ultratrace elements. Nutr Rev 1988; 46:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/10\">",
"      Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care 2004; 27:2741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/11\">",
"      Balk EM, Tatsioni A, Lichtenstein AH, et al. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007; 30:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/12\">",
"      Lukaski HC, Bolonchuk WW, Siders WA, Milne DB. Chromium supplementation and resistance training: effects on body composition, strength, and trace element status of men. Am J Clin Nutr 1996; 63:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/13\">",
"      Hallmark MA, Reynolds TH, DeSouza CA, et al. Effects of chromium and resistive training on muscle strength and body composition. Med Sci Sports Exerc 1996; 28:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/14\">",
"      Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr 2004; 79:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/15\">",
"      Hathcock JN. Safety limits for nutrients. J Nutr 1996; 126:2386S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/16\">",
"      Gad SC. Acute and chronic systemic chromium toxicity. Sci Total Environ 1989; 86:149.",
"     </a>",
"    </li>",
"    <li>",
"     United States Environmental Protection Agency. Toxicological review of hexavalent chromium, 1998 file://www.epa.gov/iris (Accessed on January 27, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/18\">",
"      Stearns DM, Wetterhahn KE. Reaction of chromium(VI) with ascorbate produces chromium(V), chromium(IV), and carbon-based radicals. Chem Res Toxicol 1994; 7:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/19\">",
"      Randall JA, Gibson RS. Serum and urine chromium as indices of chromium status in tannery workers. Proc Soc Exp Biol Med 1987; 185:16.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board of the Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academies Press, Washington DC, 2000. www.nap.org (Accessed on May 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/21\">",
"      Johnson MA, Kays SE. Copper: its role in human nutrition. Nutrition Today 1990; 25:6.",
"     </a>",
"    </li>",
"    <li>",
"     Turnlund JR. Copper. In: Modern nutrition in health and disease, 10th, Shils ME, Shike M, Ross AC, et al (Eds), Lippincott Williams and Wilkins, Baltimore 2006. p.286.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/23\">",
"      Vuori E. Intake of copper, iron, manganese and zinc by healthy, exclusively-breast-fed infants during the first 3 months of life. Br J Nutr 1979; 42:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/24\">",
"      L&ouml;nnerdal B. Copper nutrition during infancy and childhood. Am J Clin Nutr 1998; 67:1046S.",
"     </a>",
"    </li>",
"    <li>",
"     Trace elements in human nutrition. Report of a WHO expert committee. Report No. 532, World Health Organization, Geneva, 1973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/26\">",
"      Mason KE. A conspectus of research on copper metabolism and requirements of man. J Nutr 1979; 109:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/27\">",
"      Wapnir RA. Copper absorption and bioavailability. Am J Clin Nutr 1998; 67:1054S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/28\">",
"      Chan WY, Rennert OM. The role of copper in iron metabolism. Ann Clin Lab Sci 1980; 10:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/29\">",
"      Harris ED. The iron-copper connection: the link to ceruloplasmin grows stronger. Nutr Rev 1995; 53:170.",
"     </a>",
"    </li>",
"    <li>",
"     L&ouml;nnerdal B. Iron-zinc-copper interactions. In: Micronutrient interactions: impact on child health and nutrition, ILSI Press, Washington, DC 1998.",
"    </li>",
"    <li>",
"     Prohaska JR. Biochemical functions of copper in animals. In: Essential and toxic trace elements in human health and disease, Prasad AS (Ed), Alan R Liss, New York 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/32\">",
"      Danks DM. Copper deficiency in humans. Annu Rev Nutr 1988; 8:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/33\">",
"      Kumar N, Gross JB Jr, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology 2004; 63:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/34\">",
"      Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin Proc 2006; 81:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/35\">",
"      Hoffman HN 2nd, Phyliky RL, Fleming CR. Zinc-induced copper deficiency. Gastroenterology 1988; 94:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/36\">",
"      Fiske DN, McCoy HE 3rd, Kitchens CS. Zinc-induced sideroblastic anemia: report of a case, review of the literature, and description of the hematologic syndrome. Am J Hematol 1994; 46:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/37\">",
"      Huff JD, Keung YK, Thakuri M, et al. Copper deficiency causes reversible myelodysplasia. Am J Hematol 2007; 82:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/38\">",
"      Kumar N, Elliott MA, Hoyer JD, et al. \"Myelodysplasia,\" myeloneuropathy, and copper deficiency. Mayo Clin Proc 2005; 80:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/39\">",
"      Halfdanarson TR, Kumar N, Li CY, et al. Hematological manifestations of copper deficiency: a retrospective review. Eur J Haematol 2008; 80:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/40\">",
"      Barclay SM, Aggett PJ, Lloyd DJ, Duffty P. Reduced erythrocyte superoxide dismutase activity in low birth weight infants given iron supplements. Pediatr Res 1991; 29:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/41\">",
"      Williams DM. Copper deficiency in humans. Semin Hematol 1983; 20:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/42\">",
"      Kumar N, Ahlskog JE, Gross JB Jr. Acquired hypocupremia after gastric surgery. Clin Gastroenterol Hepatol 2004; 2:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/43\">",
"      Tan JC, Burns DL, Jones HR. Severe ataxia, myelopathy, and peripheral neuropathy due to acquired copper deficiency in a patient with history of gastrectomy. JPEN J Parenter Enteral Nutr 2006; 30:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/44\">",
"      Griffith DP, Liff DA, Ziegler TR, et al. Acquired copper deficiency: a potentially serious and preventable complication following gastric bypass surgery. Obesity (Silver Spring) 2009; 17:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/45\">",
"      Juhasz-Pocsine K, Rudnicki SA, Archer RL, Harik SI. Neurologic complications of gastric bypass surgery for morbid obesity. Neurology 2007; 68:1843.",
"     </a>",
"    </li>",
"    <li>",
"     Shaw JC. Copper deficiency in term and preterm infants. In: Nutritional anemias, Fomon SJ, Zlotkin S (Eds), Vevey/Raven Press, New York 1992. p.105.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/47\">",
"      Sutton AM, Harvie A, Cockburn F, et al. Copper deficiency in the preterm infant of very low birthweight. Four cases and a reference range for plasma copper. Arch Dis Child 1985; 60:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/48\">",
"      Halfdanarson TR, Kumar N, Hogan WJ, Murray JA. Copper deficiency in celiac disease. J Clin Gastroenterol 2009; 43:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/49\">",
"      Goodman BP, Mistry DH, Pasha SF, Bosch PE. Copper deficiency myeloneuropathy due to occult celiac disease. Neurologist 2009; 15:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/50\">",
"      Yaldizli O, Johansson U, Gizewski ER, Maschke M. Copper deficiency myelopathy induced by repetitive parenteral zinc supplementation during chronic hemodialysis. J Neurol 2006; 253:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/51\">",
"      Willis MS, Monaghan SA, Miller ML, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol 2005; 123:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/52\">",
"      Nations SP, Boyer PJ, Love LA, et al. Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease. Neurology 2008; 71:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/53\">",
"      Hedera P, Peltier A, Fink JK, et al. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin II. The denture cream is a primary source of excessive zinc. Neurotoxicology 2009; 30:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/54\">",
"      Pawa S, Khalifa AJ, Ehrinpreis MN, et al. Zinc toxicity from massive and prolonged coin ingestion in an adult. Am J Med Sci 2008; 336:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/55\">",
"      van den Hamer CJ, Hoogenraad TU. Copper deficiency in Wilson's disease. Lancet 1989; 2:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/56\">",
"      Foubert-Samier A, Kazadi A, Rouanet M, et al. Axonal sensory motor neuropathy in copper-deficient Wilson's disease. Muscle Nerve 2009; 40:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/57\">",
"      Konagaya M, Matsumoto A, Takase S, et al. Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban. J Neurol Sci 2004; 218:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/58\">",
"      Kumar N, Knopman D. SMON, clioquinol, and copper. Postgrad Med J 2005; 81:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/59\">",
"      Schaumburg H, Herskovitz S. Copper deficiency myeloneuropathy: a clue to clioquinol-induced subacute myelo-optic neuropathy? Neurology 2008; 71:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/60\">",
"      Lang TF, Glynne-Jones R, Blake S, et al. Iatrogenic copper deficiency following information and drugs obtained over the Internet. Ann Clin Biochem 2004; 41:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/61\">",
"      Fleming CR. Trace element metabolism in adult patients requiring total parenteral nutrition. Am J Clin Nutr 1989; 49:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/62\">",
"      Fuhrman MP, Herrmann V, Masidonski P, Eby C. Pancytopenia after removal of copper from total parenteral nutrition. JPEN J Parenter Enteral Nutr 2000; 24:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/63\">",
"      Mercer JF. The molecular basis of copper-transport diseases. Trends Mol Med 2001; 7:64.",
"     </a>",
"    </li>",
"    <li>",
"     Danks D. Hereditary disorders of copper metabolism in Wilson's disease and Menkes' disease. In: The metabolic basis of inherited disease, 5th, Stanbury JB, Wyngaarden JB, Fredrickson DS, et al (Eds), MacGraw-Hill, New York 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/65\">",
"      de Bie P, Muller P, Wijmenga C, Klomp LW. Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes. J Med Genet 2007; 44:673.",
"     </a>",
"    </li>",
"    <li>",
"     Turnland JR. Copper. In: Modern nutrition in health and disease, Shils ME, Olson JA, Shike M, Ross AC (Eds), Williams and Wilkins, Baltimore 1999. p.241.",
"    </li>",
"    <li>",
"     Turnlund JR. Copper. In: Modern nutrition in health and disease, Shils ME, Olson JA, Shike M (Eds), Lippincott, Philadelphia 2000. p.241.",
"    </li>",
"    <li>",
"     Davis GK, Mertz W. Copper. In: Trace elements in human and animal nutrition, 5th, Mertz W (Ed), Academic Press, San Diego 1987. Vol 1, p.301.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/69\">",
"      Harris ED. Cellular copper transport and metabolism. Annu Rev Nutr 2000; 20:291.",
"     </a>",
"    </li>",
"    <li>",
"     Linder MC. Copper. In: Present knowledge in nutrition, Ziegler EE, Filer LJ Jr (Eds), ILSI Press, Washington, DC 1996. p.307.",
"    </li>",
"    <li>",
"     Stamp TC. Fluoride. In: Encyclopedia of food science, food technology, and nutrition, Macrae R, Robinson RK, Sadler MJ (Eds), Academic Press, London 1993. p.1932.",
"    </li>",
"    <li>",
"     Subcommittee on the Tenth Edition of the RDAs. Fluoride. In: Recommended dietary allowances, 10th, National Academy Press, Washington, DC 1989. p.235.",
"    </li>",
"    <li>",
"     Phipps KR. Flouoride. In: Present knowledge in nutrition, Ziegler EE, Filer LJ Jr (Eds), ILSI Press, Washington, DC 1996. p.329.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/74\">",
"      Position of the American Dietetic Association: the impact of fluoride on health. J Am Diet Assoc 2000; 100:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/75\">",
"      Kleerekoper M. The role of fluoride in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998; 27:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/76\">",
"      Haguenauer D, Welch V, Shea B, et al. Fluoride for treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2000; :CD002825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/77\">",
"      Merialdi M, Caulfield LE, Zavaleta N, et al. Randomized controlled trial of prenatal zinc supplementation and fetal bone growth. Am J Clin Nutr 2004; 79:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/78\">",
"      Jenkins GN. Review of fluoride research since 1959. Arch Oral Biol 1999; 44:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/79\">",
"      Burt BA. The case for eliminating the use of dietary fluoride supplements for young children. J Public Health Dent 1999; 59:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/80\">",
"      Augenstein WL, Spoerke DG, Kulig KW, et al. Fluoride ingestion in children: a review of 87 cases. Pediatrics 1991; 88:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/81\">",
"      Hetzel BS, Potter BJ, Dulberg EM. The iodine deficiency disorders: nature, pathogenesis and epidemiology. World Rev Nutr Diet 1990; 62:59.",
"     </a>",
"    </li>",
"    <li>",
"     Hetzel BS. The story of diodide3 deficiency- an international challenge in nutrition, Oxford University Press, Oxford 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/83\">",
"      Zimmermann MB, Jooste PL, Pandav CS. Iodine-deficiency disorders. Lancet 2008; 372:1251.",
"     </a>",
"    </li>",
"    <li>",
"     Stanbury JB. Iodine deficiency and the iodine deficiency disorders. In: Present knowledge in nutrition, Ziegler EE, Filer LJ Jr (Eds), ILSI Press, Washington, DC 1996. p.378.",
"    </li>",
"    <li>",
"     Kavishe FP. Iodine. In: Encyclopedia of food science, food technology, and nutrition, Macrae R, Robinson RK, Sadler MJ (Eds), Academic Press, London 1993. p.2558.",
"    </li>",
"    <li>",
"     Subcommittee on the Tenth Edition of the RDAs. Iodine. In: Recommended dietary allowances, 10th, National Academy Press, Washington, DC 1989. p.213.",
"    </li>",
"    <li>",
"     Yip R, Dallman PR.. Iron. In: Present knowledge in nutrition, Ziegler EE, Filer LJ Jr (Eds), International Life Sciences Institute, Washington, DC 1996. p.277.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/88\">",
"      Subar AF, Krebs-Smith SM, Cook A, Kahle LL. Dietary sources of nutrients among US children, 1989-1991. Pediatrics 1998; 102:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/89\">",
"      Rolfs A, Hediger MA. Intestinal metal ion absorption: an update. Curr Opin Gastroenterol 2001; 17:177.",
"     </a>",
"    </li>",
"    <li>",
"     Fairbanks VF. Iron in medicine and nutrition. In: Modern nutrition in health and disease, 9th, Shils ME, Olson JA, Shike M, Ross AC (Eds), Williams and Wilkins, Baltimore 1999. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/91\">",
"      Kime RA, Gibson AT, Powers HJ. The quantification of non-transferrin-bound iron in plasma from neonates, using high performance liquid chromatography. Proc Nutr Soc 1996; 55:95A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/92\">",
"      Weinberg ED. Iron withholding: a defense against infection and neoplasia. Physiol Rev 1984; 64:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/93\">",
"      Winterbourn CC. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol Lett 1995; 82-83:969.",
"     </a>",
"    </li>",
"    <li>",
"     Yehuda S. Neurochemical basis of behavioural effects of brain iron deficiency in animals. In: Brain, behaviour, and iron in the infant diet, Dobbings J (Ed), Springer Verlag, London 1990. p.63.",
"    </li>",
"    <li>",
"     Dallman PR. Iron. In: Present knowledge in nutrition, 6th, Brown ML (Ed), International Life Sciences Institute/Nutritional Foundation, Washington, DC 1990. p.241.",
"    </li>",
"    <li>",
"     Aggett PJ. Neonatal trace element metabolism. In: Principles of perinatal-neonatal metabolism, Cowett RM (Ed), Springer-Verlag, New York 19991. p.500.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/97\">",
"      Cook JD, Lynch SR. The liabilities of iron deficiency. Blood 1986; 68:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/98\">",
"      Lozoff B, Klein NK, Nelson EC, et al. Behavior of infants with iron-deficiency anemia. Child Dev 1998; 69:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/99\">",
"      Walter T. Effect of iron-deficiency anaemia on cognitive skills in infancy and childhood. Baillieres Clin Haematol 1994; 7:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/100\">",
"      Lozoff B, Jimenez E, Hagen J, et al. Poorer behavioral and developmental outcome more than 10 years after treatment for iron deficiency in infancy. Pediatrics 2000; 105:E51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/101\">",
"      Scholl TO, Hediger ML, Fischer RL, Shearer JW. Anemia vs iron deficiency: increased risk of preterm delivery in a prospective study. Am J Clin Nutr 1992; 55:985.",
"     </a>",
"    </li>",
"    <li>",
"     Keen CL, Zidenburg-Cherr S.. Manganese. In: Present knowledge in nutrition, Ziegler EE, Filer LJ Jr (Eds), International Life Sciences Institute, Washington, DC 1996. p.334.",
"    </li>",
"    <li>",
"     Nielsen FH. Ultratrace minerals. In: Modern nutrition in health and disease, 9th, Shils ME, Olson JA, Shike M, Ross AC (Eds), Williams and Wilkins, Baltimore 1999. p.283.",
"    </li>",
"    <li>",
"     Keen CL, Zidenburg-Cherr S. Manganese. In: Encyclopedia of food science, food technology, and nutrition, Macrae R, Robinson RK, Sadler MJ (Eds), Academic Press, London 1993. p.2863.",
"    </li>",
"    <li>",
"     Committee on Nutrition American Academy of Pediatrics. Trace elements. In: Pediatric Nutrition Handbook, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.423.",
"    </li>",
"    <li>",
"     Wedler FC. Biochemical and nutritional role of manganese: An overview. In: Manganese in health and disease, Klimis-Tavantzis DJ (Ed), CRC Press, Boca Raton 1994. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/107\">",
"      Soldin OP, Aschner M. Effects of manganese on thyroid hormone homeostasis: potential links. Neurotoxicology 2007; 28:951.",
"     </a>",
"    </li>",
"    <li>",
"     Finley JW, Johnson PE. Manganese deficiency and excess in rodents. In: Manganese in health and disease, Klimis-Tavantzis DJ (Ed), CRC Press, Boca Raton 1994. p.85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/109\">",
"      Friedman BJ, Freeland-Graves JH, Bales CW, et al. Manganese balance and clinical observations in young men fed a manganese-deficient diet. J Nutr 1987; 117:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/110\">",
"      Hall AJ, Margetts BM, Barker DJ, et al. Low blood manganese levels in Liverpool children with Perthes' disease. Paediatr Perinat Epidemiol 1989; 3:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/111\">",
"      Perry CA, Taylor JF, Nunn A, et al. Perthes' disease and blood manganese levels. Arch Dis Child 2000; 82:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/112\">",
"      Woolf A, Wright R, Amarasiriwardena C, Bellinger D. A child with chronic manganese exposure from drinking water. Environ Health Perspect 2002; 110:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/113\">",
"      McMillan DE. A brief history of the neurobehavioral toxicity of manganese: some unanswered questions. Neurotoxicology 1999; 20:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/114\">",
"      Fell JM, Reynolds AP, Meadows N, et al. Manganese toxicity in children receiving long-term parenteral nutrition. Lancet 1996; 347:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/115\">",
"      Masumoto K, Suita S, Taguchi T, et al. Manganese intoxication during intermittent parenteral nutrition: report of two cases. JPEN J Parenter Enteral Nutr 2001; 25:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/116\">",
"      Aschner JL, Aschner M. Nutritional aspects of manganese homeostasis. Mol Aspects Med 2005; 26:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/117\">",
"      Dickerson RN. Manganese intoxication and parenteral nutrition. Nutrition 2001; 17:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/118\">",
"      Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr 2004; 28:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/119\">",
"      Hardy IJ, Gillanders L, Hardy G. Is manganese an essential supplement for parenteral nutrition? Curr Opin Clin Nutr Metab Care 2008; 11:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/120\">",
"      Howard L, Ashley C, Lyon D, Shenkin A. Autopsy tissue trace elements in 8 long-term parenteral nutrition patients who received the current U.S. Food and Drug Administration formulation. JPEN J Parenter Enteral Nutr 2007; 31:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/121\">",
"      Schwartz K, Foltz CM. Selenium as an integral part of factor 3 against dietary necrotic liver degeneration. J Am Chem Soc 1957; 79:3293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/122\">",
"      Rayman MP. Selenium and human health. Lancet 2012; 379:1256.",
"     </a>",
"    </li>",
"    <li>",
"     Levander OA, Burk RF. Selenium. In: Present knowledge in nutrition, Ziegler EE, Filer LJ Jr (Eds), ILSI Press, Washington, DC 1996. p.320.",
"    </li>",
"    <li>",
"     Thomson C, Robinson M. Selenium. In: Encyclopedia of food science, food technology, and nutrition, Macrae R, Robinson RK, Sadler MJ (Eds), Academic Press, London 1993. p.4014.",
"    </li>",
"    <li>",
"     Subcommittee on the Tenth Edition of the RDAs. Selenium. In: Recommended dietary allowances, 10th, National Academy Press, Washington, DC 1989. p.217.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/126\">",
"      Barceloux DG. Zinc. J Toxicol Clin Toxicol 1999; 37:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/127\">",
"      Holben DH, Smith AM. The diverse role of selenium within selenoproteins: a review. J Am Diet Assoc 1999; 99:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/128\">",
"      Allan CB, Lacourciere GM, Stadtman TC. Responsiveness of selenoproteins to dietary selenium. Annu Rev Nutr 1999; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/129\">",
"      Rayman MP. The importance of selenium to human health. Lancet 2000; 356:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/130\">",
"      Hawkes WC, Hornbostel L. Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Biol Psychiatry 1996; 39:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/131\">",
"      Finley JW, Penland JG. Adequacy or deprivation of dietary selenium in healthy men: Clinical and psychologica findings. J Trace Elem Exp Med 1998; 11:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/132\">",
"      Sappey C, Legrand-Poels S, Best-Belpomme M, et al. Stimulation of glutathione peroxidase activity decreases HIV type 1 activation after oxidative stress. AIDS Res Hum Retroviruses 1994; 10:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/133\">",
"      Taylor EW, Nadimpalli RG, Ramanathan CS. Genomic structures of viral agents in relation to the biosynthesis of selenoproteins. Biol Trace Elem Res 1997; 56:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/134\">",
"      Ishida T, Himeno K, Torigoe Y, et al. Selenium deficiency in a patient with Crohn's disease receiving long-term total parenteral nutrition. Intern Med 2003; 42:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/135\">",
"      Observations on effect of sodium selenite in prevention of Keshan disease. Chin Med J (Engl) 1979; 92:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/136\">",
"      Beck MA, Shi Q, Morris VC, Levander OA. Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nat Med 1995; 1:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/137\">",
"      van Rij AM, Thomson CD, McKenzie JM, Robinson MF. Selenium deficiency in total parenteral nutrition. Am J Clin Nutr 1979; 32:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/138\">",
"      de Berranger E, Colinet S, Michaud L, et al. Severe selenium deficiency secondary to chylous loss. JPEN J Parenter Enteral Nutr 2006; 30:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/139\">",
"      Look MP, Rockstroh JK, Rao GS, et al. Serum selenium versus lymphocyte subsets and markers of disease progression and inflammatory response in human immunodeficiency virus-1 infection. Biol Trace Elem Res 1997; 56:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/140\">",
"      Spallholz JE, Boylan LM, Larsen HS. Advances in understanding selenium's role in the immune system. Ann N Y Acad Sci 1990; 587:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/141\">",
"      Kiremidjian-Schumacher L, Roy M, Wishe HI, et al. Supplementation with selenium and human immune cell functions. II. Effect on cytotoxic lymphocytes and natural killer cells. Biol Trace Elem Res 1994; 41:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/142\">",
"      Mazokopakis EE, Papadakis JA, Papadomanolaki MG, et al. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis. Thyroid 2007; 17:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/143\">",
"      Vogt TM, Ziegler RG, Patterson BH, Graubard BI. Racial differences in serum selenium concentration: analysis of US population data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2007; 166:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/144\">",
"      Combs GF Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther 1998; 79:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/145\">",
"      N&egrave;ve J. Selenium as a risk factor for cardiovascular diseases. J Cardiovasc Risk 1996; 3:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/146\">",
"      Yang GQ, Wang SZ, Zhou RH, Sun SZ. Endemic selenium intoxication of humans in China. Am J Clin Nutr 1983; 37:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/147\">",
"      MacFarquhar JK, Broussard DL, Melstrom P, et al. Acute selenium toxicity associated with a dietary supplement. Arch Intern Med 2010; 170:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/148\">",
"      Centers for Disease Control (CDC). Selenium intoxication--New York. MMWR Morb Mortal Wkly Rep 1984; 33:157.",
"     </a>",
"    </li>",
"    <li>",
"     Hambidge KM, Casey CE, Krebs NF. Zinc in trace elements. In: Human and animal nutrition, 5th, Mertz W (Ed), Academic Press, Orlando 1986. Vol 2, p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/150\">",
"      Prasad AS. Clinical manifestations of zinc deficiency. Annu Rev Nutr 1985; 5:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/151\">",
"      Prasad AS. Clinical, endocrinological and biochemical effects of zinc deficiency. Clin Endocrinol Metab 1985; 14:567.",
"     </a>",
"    </li>",
"    <li>",
"     King, JC, Klein, CL. Zinc. In: Modern nutrition in health and disease, Shils ME, Olson JA, Shike M, et al. Lippincott, Philadelphia 2000. p.223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/153\">",
"      Briefel RR, Bialostosky K, Kennedy-Stephenson J, et al. Zinc intake of the U.S. population: findings from the third National Health and Nutrition Examination Survey, 1988-1994. J Nutr 2000; 130:1367S.",
"     </a>",
"    </li>",
"    <li>",
"     Cousins RJ. Zinc. In: Present knowledge in nutrition, Ziegler EE, Filer LJ Jr (Eds), ILSI Press, Washington 1996. p.293.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/155\">",
"      Lee HH, Prasad AS, Brewer GJ, Owyang C. Zinc absorption in human small intestine. Am J Physiol 1989; 256:G87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/156\">",
"      Weigand E. Absorption of trace elements: zinc. Int J Vitam Nutr Res Suppl 1983; 25:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/157\">",
"      Sandstr&ouml;m B. Bioavailability of zinc. Eur J Clin Nutr 1997; 51 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/158\">",
"      Cousins RJ, Lee-Ambrose LM. Nuclear zinc uptake and interactions and metallothionein gene expression are influenced by dietary zinc in rats. J Nutr 1992; 122:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/159\">",
"      Berg JM, Shi Y. The galvanization of biology: a growing appreciation for the roles of zinc. Science 1996; 271:1081.",
"     </a>",
"    </li>",
"    <li>",
"     King JC, Klein CL. Zinc. In: Modern nutrition in health and disease, Shils ME, Olson JA, Shike M, et al (Eds), Lippincott, Philadelphia 2000. p.223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/161\">",
"      Zalewski PD, Forbes IJ, Giannakis C. Physiological role for zinc in prevention of apoptosis (gene-directed death). Biochem Int 1991; 24:1093.",
"     </a>",
"    </li>",
"    <li>",
"     Color atlas and synopsis of clinical dermatology, 3rd, Fitzpatrick TB, Johnson RA, Wolf K (Eds), McGraw Hill, New York 1997. p.442.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/163\">",
"      Ruz M, Carrasco F, Rojas P, et al. Zinc absorption and zinc status are reduced after Roux-en-Y gastric bypass: a randomized study using 2 supplements. Am J Clin Nutr 2011; 94:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/164\">",
"      VALLEE BL, WACKER WE, BARTHOLOMAY AF, HOCH FL. Zinc metabolism in hepatic dysfunction. II. Correlation of metabolic patterns with biochemical findings. N Engl J Med 1957; 257:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/165\">",
"      Macdonald JB, Connolly SM, DiCaudo DJ. Think zinc deficiency: acquired acrodermatitis enteropathica due to poor diet and common medications. Arch Dermatol 2012; 148:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/166\">",
"      King JC. Assessment of techniques for determining human zinc requirements. J Am Diet Assoc 1986; 86:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/167\">",
"      Walter RM Jr, Uriu-Hare JY, Olin KL, et al. Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. Diabetes Care 1991; 14:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/168\">",
"      Cunningham JJ, Fu A, Mearkle PL, Brown RG. Hyperzincuria in individuals with insulin-dependent diabetes mellitus: concurrent zinc status and the effect of high-dose zinc supplementation. Metabolism 1994; 43:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/169\">",
"      Goldenberg RL, Tamura T, Neggers Y, et al. The effect of zinc supplementation on pregnancy outcome. JAMA 1995; 274:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/170\">",
"      Mahomed K, Bhutta Z, Middleton P. Zinc supplementation for improving pregnancy and infant outcome. Cochrane Database Syst Rev 2007; :CD000230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/171\">",
"      Iannotti LL, Zavaleta N, Le&oacute;n Z, et al. Maternal zinc supplementation reduces diarrheal morbidity in peruvian infants. J Pediatr 2010; 156:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/172\">",
"      K&uuml;ry S, Dr&eacute;no B, B&eacute;zieau S, et al. Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat Genet 2002; 31:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/173\">",
"      Wang K, Pugh EW, Griffen S, et al. Homozygosity mapping places the acrodermatitis enteropathica gene on chromosomal region 8q24.3. Am J Hum Genet 2001; 68:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/174\">",
"      Wastney ME, Ahmed S, Henkin RI. Changes in regulation of human zinc metabolism with age. Am J Physiol 1992; 263:R1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/175\">",
"      Turnlund JR, Durkin N, Costa F, Margen S. Stable isotope studies of zinc absorption and retention in young and elderly men. J Nutr 1986; 116:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/176\">",
"      Prasad AS, Brewer GJ, Schoomaker EB, Rabbani P. Hypocupremia induced by zinc therapy in adults. JAMA 1978; 240:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/177\">",
"      Oakes EJ, Lyon TD, Duncan A, et al. Acute inflammatory response does not affect erythrocyte concentrations of copper, zinc and selenium. Clin Nutr 2008; 27:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/19/39226/abstract/178\">",
"      Foote JW, Delves HT. Albumin bound and alpha 2-macroglobulin bound zinc concentrations in the sera of healthy adults. J Clin Pathol 1984; 37:1050.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Vitamin and mineral requirements in human nutrition (2e), 2004 file://www.who.int/vmnis/en/ (Accessed on January 27, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2585 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39226=[""].join("\n");
var outline_f38_19_39226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H67\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHROMIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dietary sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dietary reference intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COPPER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Dietary sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Biological role",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Menkes disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Wilson's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dietary reference intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FLUORIDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dietary sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Biological role",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Dietary reference intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      IODINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Dietary sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Biological role",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Dietary reference intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      IRON",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Dietary sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Biological role",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      MANGANESE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Dietary sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Biological role",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Dietary reference intakes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SELENIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Dietary sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Biological role",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      - Keshan disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      - Total parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      - Other potential roles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Dietary reference intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      ZINC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Dietary sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      Biological role",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      - Acrodermatitis enteropathica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      Evaluation of zinc status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66\">",
"      Dietary reference intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H67\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2585\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2585|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/3/4145\" title=\"picture 1\">",
"      Dermatitis zinc defic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/34/40481\" title=\"picture 2\">",
"      Acrodermatitis enteropathica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2585|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/17/4380\" title=\"table 1\">",
"      Types trace minerals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/22/38241\" title=\"table 2\">",
"      DRI trace elements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/13/25822\" title=\"table 3\">",
"      Dietary sources of iron",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42378?source=related_link\">",
"      Cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11880?source=related_link\">",
"      Copper deficiency myeloneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28631?source=related_link\">",
"      Dietary history and recommended dietary intake in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39864?source=related_link\">",
"      Iodine deficiency disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=related_link\">",
"      Iodine-induced thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36585?source=related_link\">",
"      Neurologic manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/248?source=related_link\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33192?source=related_link\">",
"      Preventive dental care and counseling for infants and young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9610?source=related_link\">",
"      Risk factors for type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=related_link\">",
"      The common cold in adults: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/11/23737?source=related_link\">",
"      Treatment of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_19_39227="BIRADS mammography categories";
var content_f38_19_39227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    BI-RADS mammographic assessment categories",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Assessment category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Probability of malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0: Incomplete",
"       </td>",
"       <td>",
"        Need for further evaluation",
"       </td>",
"       <td>",
"        Not applicable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1: Normal",
"       </td>",
"       <td>",
"        Normal interval follow-up",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2: Benign",
"       </td>",
"       <td>",
"        Normal interval follow-up",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3: Probably benign",
"       </td>",
"       <td>",
"        A short interval follow-up is recommended",
"       </td>",
"       <td>",
"        &lt;2 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        4: Suspicious abnormality",
"       </td>",
"       <td rowspan=\"4\">",
"        A biopsy should be considered",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &ge;2 to &lt;95 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        (a) Low-risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        (b) Intermediate-risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        (c) Moderate to high-risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5: Highly suggestive of malignancy",
"       </td>",
"       <td>",
"        Biopsy or surgery should be performed",
"       </td>",
"       <td>",
"        &ge;95 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6: Biopsy-proven carcinoma",
"       </td>",
"       <td>",
"        Appropriate action should be taken",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BI-RADS: Breast Imaging Reporting and Data System.",
"    </div>",
"    <div class=\"reference\">",
"     Source: Breast Imaging Reporting and Data System (BI-RADS) Atlas. 4th Edition. American College of Radiology, Reston, VA, 2003",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39227=[""].join("\n");
var outline_f38_19_39227=null;
var title_f38_19_39228="Etiology of nasal obstruction";
var content_f38_19_39228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of nasal obstruction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mucosal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Inflammatory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhinosinusitis (may also have infectious etiology)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhinitis, allergic and non-allergic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nasal polyps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Histiocytosis X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nasal vestibulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antithyroid medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Antihypertensive medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Alpha-blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Angiotensin converting enzyme (ACE) inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Beta-blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Calcium channel blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hydralazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Some antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erectile dysfunction agents (Phosphodiesterase 5-inhibitors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Estrogen and progesterone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonsteroidal anti-inflammatory drugs (NSAIDs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhinitis medicamentosa (rebound nasal congestion with intranasal decongestants such as oxymetazoline or neosynephrine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Structural",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Congenital abnormalities",
"        </strong>",
"        (eg, pyriform aperture stenosis, choanal atresia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Acquired abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enlarged adenoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Foreign bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Septal disorders (eg, septal perforation due to intranasal cocaine, septal deviation due to trauma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nasal valve abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucoceles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tumors",
"        </strong>",
"        (eg, inverted papilloma, squamous cell carcinoma, adenoid cystic carcinoma, olfactory neuroblastoma)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39228=[""].join("\n");
var outline_f38_19_39228=null;
var title_f38_19_39229="Schematic figure demonstrating hd access in series with circulat";
var content_f38_19_39229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic figure demonstrating hemodialysis access in series with circulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 269px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the performance of hemodialysis in which the access is in series with the systemic circulation. In this setting, all of the blood would go through the dialyzer and urea removal would be maximized.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39229=[""].join("\n");
var outline_f38_19_39229=null;
var title_f38_19_39230="Normal foot AP";
var content_f38_19_39230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Standard AP radiograph of foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 562px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AP x-ray provides a better view of the proximal fifth metatarsal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39230=[""].join("\n");
var outline_f38_19_39230=null;
var title_f38_19_39231="Acral lentiginous melanoma in situ";
var content_f38_19_39231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acral lentiginous melanoma in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acral lentiginous melanoma in situ on the left index finger of a 74-year-old man, presenting as a linear pigmented streak (melanonychia striata) with Hutchinson sign (pigmentation of the proximal and lateral nail folds).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_19_39231=[""].join("\n");
var outline_f38_19_39231=null;
